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ABSTRACT 
The effects of Danshen on the pharmacokinetics and pharmacodynamics of 
warfarin were studied in rats. In the pharmacokinetic study, single oral doses of 
warfarin (2 mg/kg) were administered to rats with or without pre-treatment with 
Danshen extract (5 g/kg ip，twice daily for three days). Plasma warfarin 
concentrations were measured for 72 hours by high performance liquid 
chromatography (HPLC), In the pharmacodynamic study, the prothrombin times 
(PT) were measured daily both in the Danshen treatment period and after warfarin 
doses for four days. The absorption rate constant (Ka), volume of distribution (Vd) 
and elimination half-life (1¼) of warfarin were significantly decreased (Ka: 
51.4%; Vd: 61,8%; TVi： 49.7%) while the maximum concentration (Cmax) and 
the time of maximum concentration reached (Tmax) were significantly increased 
(Cmax: 100%; Tmax: 100%) after treatment with Danshen. After the Danshen 
treatment, both R- and S-warfarin concentrations were significantly increased. The 
AUCtot and TV2 of both enantiomers were significantly increased (AUCtot: R-
warfarin: 173.7%; S-warfiarinf 105.2%; TVa： R-warfarin: 45.7%; S-warfarin: 
29.7%) while Vd and CL were decreased after Danshen treatment (Yd: R-
warfarin: 44.2%; S-warfarin: 33.9%; CL: R-warfarin: 60.9%; S-warfarin: 
50.5%). There was no significant change in PT during the Danshen treatment 
period while the PTs were increased significantly in the first two days after the 
warfarin doses. In the steady state study, warfarin was administered orally (0.2 
mg/kg/day) in order to maintain a steady state； When the steady state was reached 
iii 
and maintained after five days, the rats were treated with Danshen extract (2 g/kg) 
or Commercial Danshen extract (1 g/kg) orally twice daily for three days. In the 
" r • _ ' 
pharmacodynamic study, both Danshen extracts did not show any significant 
change in the PT at steady state. But in the pharmacokinetic study, the plasma 
warfarin concentrations were significantly increased (68.3 %) after each Danshen 
extracts treatment at the steady state. After intraperitoneal Danshen treatment, both 
R- and S-warfarin concentrations and PTs were significantly increased (R-warfarin: 
33.0%; S-warfarin: 26.0%; PT: 60.7%) 
The effects of Danggui extract on pharmacokinetics and pharmacodynamics 
of warfarin were studied in rabbits. The study was divided into two parts. One 
� e involved the single subcutaneous doses (2 mg/kg) treatment of warfarin after three 
days treatment orally with Danggui extract (2 g/kg) twice daily. The other 
involved the steady state study of warfarin (0.6 mg/kg/day) after the same 
treatment with Danggui extract. In the single dose treatment, the pharmacokinetic 
parameters of warfarin were comparable in the absence and after Danggui 
treatment. The data did not show differences in warfarin's TV2, CL, Vd, or Cmax. 
Danggui extract itself did not affect the prothrombin time when it was administered 
alone. But PTs after the Danggui treatment was significantly lower than before the 
treatment. In the steady state study, only pharmacodynamic interactions between 
warfarin and Danggui were observed, but not in pharmacokinetic interaction. 
Besides, overall 33.4% of rabbits died after the three days treatment of D^iggui 
extract. From the finding of the single dose treatment, there was no evidence to 
show that Danggui has any toxic effect when it was administered alone for three 
» • '. . .- - • -
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days. The toxic mechanism of administering Danggui extract during the steady 
state of warfarin is unknown. 
The results of this study showed some evidence of drug interactions 
between warfarin and Danshen or Danggui. It also showed that dangerous drug 
interactions may occur when TCM and western medicines are coadministered. 
v 
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CHAPTER 1 
General Introduction 
1.1 Plans for the Present Study 
In February 1989，community concern was sparked off by an incident 
involving two people lapsing into a coma after consuming some herbal medicines 
thought to be "Kwai Chau Lung Dam C h o " ( 貴 州 龍 胆 草 ）• Police 
• . .. . j 
investigation ascertained that the herb actually consumed had been "Tao Er Chut" 
( 桃 耳 t ), a potent herb containing a neurotoxin (South China 
Morning Post, 1989). This wrong supply of the herb was traced back to the source 
of origin. It also raised questions over the misuse of traditional Chinese medicine 
(TCM) in Hong Kong. Many Chinese people believe that TCM as an effective 
form of health and medical care. They often add these TCM ingredients in their 
cooking. Moreover, many people use TCM as an alternative medical treatment or 
even supplement with western medical treatment (Working Party of Chinese 
Medicine Interim Report (WPCMIR), 1991), 
Warfarin is the most widely used iariticoagulant in the treatment of 
thromboembolic diseases. The adverse effect of overdosing warfarin is 
haemorrhage. From clinical reports of Prince of Wales Hospital, Hong Kong, 
haemorrhage occurred in some patients who had been put on warfarin therapy 
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steadily. The cause of haemorrhage remained unclear for a while. It turned out that 
those patients who presented with haemorrhage had self-medicated with TCM 
when they were on regular warfarin therapy. Danshen and Danggui are the most 
commonly used traditional Chinese medicines in Hong Kong. They are also freely 
available in Chinese medicine stores in Hong Kong (WPCMIR, 1991). In the 
present study, the effects of these two traditional Chinese medicines (Danshen and 
Danggui) on the pharmacokinetics and pharmacodynamics of warfarin were 
studied. 
This study, using rats and rabbits, was divided into a single dose study and 
a steady state study. The single dose study involved the investigation of changes 
on pharmacokinetic parameters (e.g. AUC, TVi, Vd and CL), plasma warfarin 
concentrations and prothrombin times (PT) after treatment with the traditional 
Chinese medicines. The steady state study was carried out to detect the effects of 
the traditional Chinese medicines on the PT and mean plasma warfarin 
concentrations in the rodents. This study simulated the patient situation during 
warfarin therapy. Since warfarin has two stereoisomers which have different 
pharmacological potency, the stereochemistry of warfarin will be considered to 
examine the effects of the traditional Chinese medicines on each stereoisomer of 
warfarin and to study if there is evidence to support drug interactions involved 
both isomers. 
2 
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1.2 Traditional Chinese Medicines 
1.2.1 Introduction 
The usefulness of certain herbs as healing agents has been known for 
thousands of years. Knowledge concerning their medicinal properties and 
instructions as to their correct application have been handed down from one 
generation to the next. Many valuable drugs are derived from ancient remedies, 
such as digitalis, quinine and atropine (Kondo, 1973). For centuries, the natives 
of India chewed snakeroot (Rauwolfla serpentina) for its calming effect. It was 
found that snakeroot contains reserpine, now widely recognized as a tranquillizer 
(Kondo, 1973). 
Traditional Chinese medicine (TCM), however, is not in the same category 
of folk medicine. It is a well-recognized system of medical knowledge based on 
observations, experiments, experience and some basic theories that evolved from 
the findings (Li, 1974),; It is not based on empirical experience alone but is a 
system developed in the distant past by individual scholars and government 
institutions. Admittedly, not all the theories are based on scientific principles, but 
the effectiveness of a number of the old remedies has been verified by modern 
science. Many of the principles which were developed centuries ago have now 
been confirmed by modern science (Li, 1974). 
. 3 , 
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Over the years, western medicine has been the mainstream of the health 
care system, but TCM still plays a significant part in the Far East. In the past two 
decades, interest in the role and development of TCM as an alternative system of 
health care and treatment has grown for academic and practical purposes. Since 
1974, traditional medicine has been incorporated into relevant World Health 
Organisation programmes. In May 1977，the 30th World Health Assembly urged 
countries to fully utilize their traditional systems of medicine with appropriate 
regulations as suited to their national health systems (World Health Organisation 
Handbook, 1985). In China, Taiwan, Singapore and Hong Kong where the 
community is predominantly of Chinese origin, TCM remains a popular form of 
alternative treatment to western medicine. This is also a growing trend in some 
Western countries, particularly where there is a large Chinese population. 
1.2.2 The Origins of Traditional Chinese Medicine 
Traditional Chinese medicine is a wealth of knowledge, and it is an 
ingredient of China's rich heritage with a long and distinguished history. For 
centuries, traditional Chinese medicinal knowledge was transferred from generation 
to generation orally and was later recorded and collated when the Chinese written 
language was invented. Because of difficulties and inefficiency in handing down 
knowledge orally from generation to generation, the early traditional Chinese 
medicine did not always function well. With the accumulation of knowledge and 
experience, people learned the various properties and effects of a wide range of 
natural substances. Besides, they started to apply them for healing and curing 
• ‘ ' . . . . , . . . … . 、 . ，• . ‘ ‘ ； \ ‘ “ . . . . • 、••' • • / 
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purposes. Basfed on the "Shi-ji"(史記；Historical Record), "Shen-nong"( 
神 農 I ； The King of Farming) gathered hundreds of thousands of herbs for 
use as drugs and food (Li, 1974). Traditional Chinese medicine which , to a great 
extent, had their genesis in foods as well as medicines, 
The first and foremost Chinese medical classic "Shen-nong Ben Cao Jing" 
(神農本草綱丨)，which is a classic on herbs composed by Shen-nong, was 
written in the 1st century A.D. (Hsu et al.r 1986). It contained both the principles 
of application as well as the origins, properties and healing effects of some 365 
types of medicines which were collected and summarized on the basis of practical 
\ • 
curing experience. Other than herbal medicines, a small number of animals and 
mineral substances were also included and graded based on their properties and 
effects. 
Parallel with the fast-developing pace of society, medicines were more 
widely used and medical experience enhanced. At the start of the 6th century 
A.D., Tao Hong-jing composed an exhaustive medical work entitled "Ben Cao 
Jing Ji Zhu" ( 本 草 經 集 注 I; A commentary on Shen-nong's herbs) (Hsu 
et ah, 1986). This was the first supplementary after the "Shen-nong Ben Cao 
Jing". It carried on the great tradition of the past and paved a new way for further 
progress. It also laid a solid foundation for the classification of traditional Chinese 
•- 、丨 、 
herbal medicines. In the 7th century during the Tang dynasty ( 唐 朝 | )， the 
‘ - • ,' I 
imperial government appointed 22 conspicuous scholars to undertake the task of-
revising and producing a new classic on herbs entitled "Tang Ben Cao" (唐本丨 
* . I . . 5 : 
草；Tang Herb Classic) (Hsu era/. , 1986). This classic contained data on 844 
different types of herbs and was the very first encyclopedia for pharmacy on 
Chinese herbal medicines sponsored by the government in China for general use 
throughout the country. 
Towards the mid-16th century, the "Tang Ben C a o " ( 唐 本 草 ） w a s 
considerably revised and expanded by Li Shih-zhen ( 李 時 珍 1) based on nearly 
800 reference books, practical investigations and studies of herbal characteristics 
and growth (Hsu, 1986). He produced an epochal work entitled "Ben Cao Gong 
M u " ( 本 草 綱 目 ； A Compendium of Medicinal Herbs). It is composed of 
52 volumes with 16 parts and 62 categories which collectively contained 
descriptions of 1,892 varieties of herbs, 1,120 illustrations and 11,090 
prescriptions. It represented the achievement of Chinese herbal medicine for the 
first sixteen centuries. It has been published in more than 30 editions over the past 
300 years, and widely circulated all over the world through its French, Russian, 
German, English and Japanese translations. 
Great importance is attached to research in traditional Chinese medicine in 
the People's Republic of China (PRC) today. Traditional Chinese medicines are 
widely used not only in the PRC, but also in various countries, such as Korea, 
Japan, and those in Europe and the Americas (World Health Organisation 
Handbook, 1985). 
- 6 ‘ 
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1.2.3 The Categorization of Traditional Chinese Medicine 
Traditional Chinese medicine can be broadly classified into two categories: 
herbal drugs and health foods (WPCMIR, 1991). There are over 2,000 different 
kinds of foods which.are often used as herbal drugs medicines. Common examples 
� ) 
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in this categories are Chiretta (Dangguf)(當歸),Huangchi slices ( i t 芪 ;) 
Dahshen ( : 丹 參 ) , Y a m slices ( 淮 山 ),Fructus lycii ( 杞 子 ） 
. 1 ‘ I • 
Eucommia ( 杜 仲 ) , T u c k a h o e (雲等丨),Tienchi ( 田 t ! ) and Pearl 
•’ ， • . ‘ 
( 珍 珠 丨 ) . T h e normal method of taking traditional Chinese medicines is in 
a boiled brotti incorporating the crude ingredients. The ingredients themselves may 
also be ground into powder form or cooked or treated with other foods according 
to the appropriate prescription. 
Certain crude medicines have a high nutrient value. The health foods 
category comprises a wide variety of products which differ greatly in value 
depending on each product's scarcity (WPCMIR, 1991). Examples of these rare ... : ./ «. 
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health food are wild Ginseng (人參 :) ,Deer 's antlers ( 鹿 茸 | ) , Swallow's 
nests ( 燕 窝 ),Fok san denorobium ( 霍 山 石 制 ] ) a n d Worm 
herbs ( 蟲 草 | ). Due to their rarity, these products are highly priced. 
Nevertheless, they remain popular by virtue of their high nutrient value. 
‘ . � 
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1.2.4 Yin and Yang 
‘ vt . 
The doctrine of yin yang ( 陰 陽 I) is the fundamental principle employed 
by all classical Chinese arts and sciences (Hyatt, 1978). Yin and yang are ideal 
states. In reality neither yin nor yang exists in absolute, only in relativity to the 
other. These conditions are mutually complementary and antagonistic. Yang is the 
positive active state, characterized by heat, light, and the exterior. Its gender is 
male. Yin is the negative inactive state, more precisely the absence of yang, 
characterized by cold, darkness, and the interior. Its gender is female (Li, 1974). 
Neither exist as a static condition, for both are in a perpetual state of 
transformation, continually blending with each other in greater or lesser 
proportions. This is always some yin in yang and some yang in yin. People are 
subject to and reflect the cyclic variations of this principle. They are more active 
during the day and in summer, more passive during the night and the winter. 
Besides, the organs follow the variations of this change. Thus, illness or 
malfunction of the organs can be caused by an abnormal accumulation of yin and 
yang, a temporary condition that can be transformed by compliance with the 
natural activity of yin and yang (Hyatt, 1978). 
The healthy body is constantly changing from yin to yang and from yang 
to yin (Hyatt, 1978), If at any time the body condition diverts from this course and 
becomes increasingly yin or yang, disease arises. This simple concept is the 
fundamental theory for prescribing herbal medicine (Li, 1974). For example, yang 
herbs such as ginseng ( 人 參 ）,which are tonics or hypertensives, are used 
# v. . - .. ‘ . ... . . . . � • . • 
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for persons suffering from 'yin conditions such as low blood pressure (Wu, 1979). 
. '
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Yin herbs such as ta huang ( ^C 黃丨 )are used for persons suffering from 
yang conditions such as high blood pressure or chronic constipation (Wu, 1979). 
Every herb has its particular yin yang character. When herbs are used in 
combination, infinite variations are possible, and appropriate herbal remedy can 
be formulated for any possible condition of disease (Hyatt, 1978). 
In recent years, many Chinese people consume TCM as alternative self-
medical treatment or even coadministered with western drugs (WPCMIR, 1991� 
They thought that under the combination of Chinese and western drugs they 
recover faster than if treated with TCM or western drugs only. Danshen and \ • -’ 
Danggui are the most commonly used Chinese medicines in Hong Kong. Their 
chemistry and pharmacological actions are discussed in Chapter 2 and Chapter 4. 
9 ' 
' _ . '  ,ri. ' . • 9 • 
:.,. '•. . / • - ‘ • .•、. ，， . , . 
1.3 Warfarin 
1.3.1 Chemistry and Pharmacology 
The clinical use of the coumarin anticoagulants can be traced back to the 
discovery of an anticoagulant substance in spoiled sweet clover silage (Link, 
1959). It produced a deficiency of plasma prothrombin and a consequent 
haemorrhagic disease in cattle. The toxic agent was identified as 
bishydroxycoumarin and synthesized as dicoumarol. Warfarin is the most widely 
used oral coumarin anticoagulant. It is also widely used as a rodenticide (Coon 
and Willus, 1970). 
Warfarin is generally administered as the sodium salt (Figure 1.1). 
Warfarin sodium is a white, odourless, amorphous or crystalline powder with a 
slight bitter taste. It is discoloured by light. The racemate is used clinically. 
Pharmacologically, warfarin acts as an indirect antagonist of vitamin K (Figure 
1.2). Vitamin K is converted to vitamin Ku 2,3-epoxide during the activation of 
clotting factor precursors (Stenflo, 1977). The epoxide is metabolized by the 
enzyme vitamin K epoxide reductase to regenerate active vitamin K (Bell, 1978). 
Warfarin inhibits epoxide reductase, thus reducing the amount of vitamin K 
available for clotting factor synthesis (Park et al., 1979). Clotting factor synthesis 
is reduced since vitamin K is required for 7-carboxylation of the coagulation 
proteins. 
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Figure 1,1 Chemical Sturcture of Warfarin Sodium 
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Warfarin reduces the synthesis of the vitamin K-dependent clotting factors 
(II, VII, IX and X proteins) in the liver (Stenflo and Suttie, 1977). The onset of 
action does not commence until existing clotting factors have been catabolized. The 
rate-limiting step is the degradation of factor VII which has the shortest half-life. 
The aim of treatment is to achieve a partial inhibition of clotting factor synthesis 
such that the prothrombin time is prolonged by a factor of 2-3 times the normal 
value. In most patients, this is achieved with a dose in the range 3-12 mg daily. 
However, daily requirements may range from 0.5 to 30 mg, with some resistant 
patients requiring very high doses (> 100 mg) (Breckenridge, 1977). 
1.3.2 Pharmacokinetics 
The most common analytical method utilizes high performance liquid 
chromatography (HPLC) (Chan and Woo, 1988; Shearer, 1983). The HPLC 
method separates warfarin from the hydroxy and alcohol metabolites but does not 
separate the R- and S-enantiomers of warfarin. In general, the HPLC method is 
technically easier than gas-liquid chromatography. The spectrophotometric methods 
lack specificity and should not be used (Banfield and Rowland, 1983). The R- and 
S-enantiomers of warfarin may also be separated by modified HPLC (Banfield and 
Rowland, 1983), and measured by radioimmunoassay. 
Warfarin is almost completely absorbed after oral administration with a 
systemic bioavailability of >95% (O'Reilly and Aggeler, 1963; Breckenridge and 
Orme, 1973). Peak plasma concentrations are achieved 3-9 hours post-dosing. 
�..., • 13 • . J 
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Volume of distribution ranges from 8 to 27% body weight and roughly equates 
with that of albumin (Hewick and McEwan, 1973; O'Reilly, 1974). Warfarin is 
highly protein (albumin) bound with values ranging form 95 to 97% (O'Reilly, 
1973; Scott, 1984). There may also be binding within the liver. Warfarin is not 
distributed into breast milk (Orme et a/., 1977). Warfarin binding is reduced in 
renal failure due to the presence of an endogenous protein-binding inhibitor 
(Bachmann et al., 1977) and in hypoalbuminaemic states (Piroli et al, 1981). 
Elimination of warfarin is by hepatic metabolism with elimination of the 
.metabolites in bile and urine. Elimination half-lives range from 10 to 45 hours for 
total warfarin (Breckenridge and Orme, 1973). However, the more potent S-
enantiomer has a shorter half life of 18-35 hours compared with 20-60 hours for 
the R-enantiomer (Hignite et al, 1980). Total plasma warfarin clearance ranges 
from 2.5 to 6.4 ml/hr-kg. 
1.3.3 Concentration-effect relationship 
The effect of warfarin on coagulation is controlled by the prothrombin time 
(PT) under standard conditions. Most clinics report a control range of 2.0-3.0 
times normal even though others use a range of 1,8 up to 3.5 (Chang et al ； 1984). 
The range used should depend on the specific type of disease being treated. There 
is no direct relationship between plasma warfarin concentration and prothrombin 
time measurement, because the measured PT reflects a balance between the rate 
of clotting factor synthesis (R^J and the rate of degradation. Warfarin affects only 
V , : . . • 14 . 
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the rate of synthesis which can be calculated from a knowledge of the PT and by 
making an assumption regarding the rate of degradation (Nagashima et al., 1969; 
Choonara et al., 1985). The logarithm of plasma warfarin concentration correlates 
well with inhibition of Rsyn. 
Routine measurement of plasma warfarin concentrations is not necessary 
because the dynamic end-point can be determined (PT). Measurement of warfarin 
concentration is required in patients who do not respond to normal doses of 
warfarin. This helps to differentiate non-compliance (common) from genuine 
resistance (rare). Therapeutic plasma concentration at steady state are of the order 
of 300 ng/ml to 3 ng/ml with wide interindividual variation (Chang et al” 1984). 
Measurement of plasma warfarin concentration is sometimes of use in the 
investigation of patients with prolonged prothrombin times. 
1.3.4 Metabolism 
Warfarin is extensively metabolized in the liver, including oxidation and 
reduction (Figure 1.3). After administration of racemic warfarin, an average of 
50% of the dose was recovered in urine in the form of oxidative and reductive 
metabolites (Toon et al, 1986). Within the 50% recovered, 19% arose from the 
R-enantiomer and 31% from the S-enantiomer. S-7-hydroxywarfarin was the major 
urinary metabolite. It is thought that two distinct reductases are involved in the 
metabolism of R- and S-warfarin. The R- and S-enantiomers of warfarin are 
metabolized by different metabolic pathways. R-warfarin is reduced by soluble 
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enzymes to warfarin (R&S) alcohols (Hewick and Moreland, 1975). A small 
percentage is converted to hydroxy metabolites, particularly 6-hydoxywarfarin. S-
warfarin is mainly metabolized to 7-hydroxywarfarin by a cytochrome-P-450-
dependent, mixed function oxidase (Lewis et al.f 1974; Banfield et al.，1983). 
Small amounts of other hydroxy metabolites and a warfarin alcohol are also 
formed. 
The warfarin alcohols and hydroxy metabolites are excreted in the urine 
and in the bile. There is an enterohepatic circulation. About 50% of a dose may 
be recovered as metabolites in urine and 35 % in bile with less than 2% as the 
unchanged drug (Banfield et al” 1983). The warfarin alcohols have anticoagulant 
activity but are considerably less potent than the parent drug. 
1.3.5 Drug Interactions 
A large number of reports of drug interactions with warfarin have been 
published (Koch-Weser and Sellers, 1977; Scott and Orme, 1983), for example, 
diuretic-warfarin interactions, antibiotic-warfarin interactions, B-blocker-warfarin 
interactions and so on. Most of these are based on isolated case reports which have 
not been studied in detail. Warfarin has a narrow therapeutic index (Gallus, 1983). 
If a drug is added to an anticoagulated patients treatment, it is essential to monitor 
the prothrombin time closely unless the added drug is known not to interact 
(Fedan, 1990). 
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Many reviews of warfarin interactions have been published (Koch-Weser 
and Sellers, 1977; Serlin and Breckenridge, 1983; Scott and Orme, 1983). The 
more important and well-documented interactions are summarized below. 
1.3.5.1 Pharmacodynamic drug-drug interactions involving warfarin 
Drug affecting platelet function may potentiate the anticoagulating effect of 
warfarin by an effect on haemostasis. Aspirin may enhance the 
hypoprothrombinemic action of warfarin by displacing warfarin from plasma 
proteins (Koch-Weser, 1971). High dose aspirin decreases prothrombin synthesis. 
Diuretics such as spironolactone may reduce the anticoagulating effect of 
warfarin by increasing the concentration of clotting factors (Serlin and 
Breckenridge, 1983). Bumetanide and fusremide had no effect in an acute dosing 
study. 
Clofibrate potentiates warfarin action by altering receptor sensitivity 
(Solomon and Rosner, 1973) The exact mechanism of this interaction is not 
known, but clofibrate appears to displace warfarin competitively from binding to 
plasma albumin (Schrogie and Solomon, 1967), depending on the concentration of 
clofibrate in the plasma. 
Broad spectrum antibiotics may suppress production of vitamin K” This 
may potentiiate the anticoagulating effect of warfarin in patients with reduced 
• V ；； . . 1 8 
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dietary intake of vitamin K (Christensen and Skovsted, 1969). Some of the newer 
cephalosporins may potentiate the anticoagulating effect of warfarin by an 
unknown mechanism (Gallus, 1983). 
Drugs which cause peptic ulceration or gastric erosions may cause 
haemorrhage in patients taking warfarin (Serlin and Breckenridge, 1983). Some of 
the interacting drugs (e.g. aspirin) also affect anticoagulants by other mechanisms 
such as displacement of plasma protein-bound warfarin. 
A high vitamin K diet, will reduce the anticoagulating effect of warfarin. 
Vitamin K antagonizes the inhibitory effect of warfarin on hepatic synthesis of 
vitamin K-dependent clotting proteins, and high doses reverse the effect of 
warfarin (Koch-Weser and Sellers, 1971). 
1.3.5.2 Pharmacokinetic drug-drug interactions involving warfarin 
(i) Increased anticoagulating effect of warfarin 
Cimetidine inhibits warfarin metabolism and potentiates its anticoagulating 
effect (Bell et al” 1981). Cimetidine binds to cytochromeP-450 and being a potent 
inhibitor of the microsomal mixed-function oxidase system, inhibits warfarin 
metabolism (Sedman, 1984). Raniditine does not have a significant inhibitory effect 
on warfarin metabolism, 
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Phenylbutazone is a well-documented example of a drug which 
stereoselectively inhibits warfarin metabolism (Banfield et al. ’ 1983). It was found 
that phenylbutazone increased the clearance of the less active R-warfarin, and 
decreased the plasma half-life. These effects are thought to be due to a 
displacement of the enantiomer from plasma and tissue binding sites, leaving more 
unbound R-warfarin available for elimination. In contrast, the clearance of the 
more active S-warfarin was reduced by phenylbutazone. These effect is presumably 
by stereoselective inhibition of the metabolism of the isomer, which overrides any 
change in protein binding. The restricted use of phenylbutazone greatly reduces the 
chance of this potentially fatal interaction. Some other non-steroid anti-
inflammatory drugs (NSAIDs) (e.g. meclofenamic acid, mefenamic acid, 
piroxicam and azapropazone) also potentiate the anticoagulant effect by displacing 
protein-bound warfarin (Sellers and Koch-Weser, 1970) . Dextropropoxyphene may 
inhibit warfarin metabolism. The commonly used Distalgesic (detropropoxyphene 
plus paracetamol) may potentiate the anticoagulating effect of warfarin. 
Paracetamol has been considered to be safe in patients taking warfarin (Koch-
Weser and Sellers, 1971). 
Co-trimoxazole and metronidazole also stereoselectively inhibit the 
metabolism of S-warfarin (Scott and Orme, 1983). Ketoconazole inhibits drug 
metabolism in vitro and there are case reports of potentiation of the anticoagulating 
effect of warfarin (Serlin and Breckenridge, 1983). Similarly, erythromycin may 
enhance the anticoagulating effect of warfarin. 
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Lipid-soluble j8-blockers (e.g. propranolol) and vaccination may inhibit 
drug metabolism (Scott ^  ah, 1984). There has been case reports of haemorrhage 
following the addition of "-blockers or influenza vaccination in patients taking 
warfarin. Some previous studies have shown only a small effect with propranolol 
and no effect with influenza vaccination (Serlin and Breckenridge, 1983; Shand 
and Rangno, 1972). 
Oral contraceptives increase clotting factor concentrations and inhibit 
warfarin metabolism (Scotland Orme, 1983). The net effect depends on the 
balance between these factors. Oral contraceptives are contraindicated in most 
\ 
patients taking warfarin because of their thrombogenic effect. 
(ii) Reduced anticoagulating effect of warfarin 
Hepatic microsomal enzyme-inducing drugs increase warfarin elimination 
and reduce the anticoagulant effect. Examples are carbamazepine, phenobarbitone : 
and rifampicin (Scott and Orme, 1983). In rats, phenylbutazone induces hepatic 
microsomal drug-metabolizing enzymes, decreasing the anticoagulant effect of 
warfarin (Welch, 1969). It affects the metabolisms of two isomers differently. 
Phenylbutazone enhances the elimination of R-warfarin while it has an inhibitory 
effect on elimination of S-warfarin (Banfield et al., 1983). 
Cholestyramine reduces the anticoagulant effect of warfarin by impairing 
warfarin absorption and interrupting its eiiterohepatic circulation (Robinson, 1971). 
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1.4 Basic Principles of Pharmacokinetics 
1.4.1 Introduction 
Pharmacokinetics is concerned with the study and characterization of the 
time course of drug concentrations in the body. Pharmacokinetic concepts and 
terminologies have been used to characterize drug absorption, distribution, 
metabolism, and elimination, and to relate these processes to the intensity and 
duration of therapeutic and toxicological effects of drugs. In clinical settings, 
pharmacokinetics has led to rational use of drugs and to safer and effective 
management of individual patients during drug treatment. Physiological models 
have been used to derive pharmacokinetic parameters of drugs (i.e. clearance, 
volume of distribution, and rate constants) which have been used to explain 
intersubject variations in pharmacological responses to drugs. They promote a 
better understanding of the effects of disease states on action of drugs, enable drug 
regimens to be tailored to needs of individual patients and help to explain treatment 
failures and adverse effects. They have been of particular value for drugs with a 
narrow margin between toxic and therapeutic effects, e.g. theophylline with 
therapeutic range of 8 to 20 mg/L (Gibaldi, 1984). 
There has been a distinct shift from classical compartmental models to 
describe and characterise drug pharmacokinetics over the past few years (Sansom 
and Nation, 1989), With the classical approach, the body was conceived as a one 
or more compartments with drug distribution and elimination occurring between 
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and from the compartments, respectively. The major disadvantage of this approach 
was that the compartments and associated parameters, such as inter-compartmental 
rate constants, have no obvious relationship to anatomical structure and 
physiological function of the animal or human being studied. Therefore, it was 
difficult to interpret and apply pharmacokinetic data physiologically (Sansom and 
Nation, 1989). Non-compartmental methods of data analysis enables the 
interpretation of derived pharmacokinetic parameters in relation to alterations in 
physiological function associated with disease states, advancing age and so on. 
1,4.2 Non-compartmental Model and Single compartmental Model (Gibaldi, 
1984) 
1.4.2.1 Intravenous Administration 
In a one compartmental model, it is assumed that the drug is completely 
and rapidly distributed to all tissues. Shortly after intravenous administration 
distribution is at equilibrium, only elimination processes need to be considered for 
describing the change in amount of drug in the body. 
-dA/dt = dAE/dt = kA.....".............[1] 
where A and AE are the amount of drug in the body and total amount of drug 
eliminated at time t, respectively; k is the elimination rate constant; -dA/dt is the 




When the distribution equilibrium is maintained, plasma concentration (C) 
of the drug reflects the total amount of drug in the body (A) and is related by a 
constant termed volume of distribution (Vd). Hence, 
A = Vd.C""."". . [2] 
By substitution of equation 2 into 1, and integrating between limits of t = 0 and 
t = t, the expression becomes: 
Log C = Log C0 - kt/2.303 [3] 
where C0 is drug concentration immediately after injection. Figure 1.4 shows a 
graphical representation of plasma concentration C, on a logarithmic scale, plotted 
against time t, on a linear scale. Pharmacokinetic parameters such as half-life. 
(1½), C0, k and Vd can be obtained using the plot as indicated in Figure 1.4. 
Besides, the elimination rate constant can be derived from: 
• k = 0.693/1½.. .....[4] 
. . ^ " • c _ • 
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1.4.2.2 Oral Administration 
After oral administration, the rate of drug amount change in the body 
(dA/dt) is a function of absorption and elimination rates. 
dA/dt = kA.AA_k.A …“…••………… ,[5] 
where kA and k are absorption and elimination rate constants, respectively. A a and 
A are the amount of drug at the absorption site and total amount of drug in the 
body, respectively. Maximum concentration occurs when the absorption and 
elimination rate constants are equal. After substitutions and integration equation 
5 becomes: 
Log C = Log (kA-F-D/Vd(kA-k)) - k-t/2.303 ………….[6] 
Figure 1.5 shows a graphical representation of plasma concentration C, on 
logarithmic scale, versus time t, on a linear scale. The intercept is a function of 
absorption and elimination constants, dose (D), amount absorbed (F) and volume 
of distribution (Vd)» Only when a drug is completely and rapidly absorbed, it can 
be assumed that the intercept (C0) approximates to the ratio of amount absorbed 
(D0) to volume of distribution (Vd) (equation 6). 
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1.4.3 Further Analysis by the Statistical Moment Theory 
Figures 1.3 and 1.4 can offer more information on the pharmacokinetics 
of a drug by further analysis. This is achieved by calculations based on a statistical 
moment theory whereby zero moment of drug plasma concentration versus time 
curve is the total area under the curve (AUC). The zero moment or AUC helps to 
calculate bioavailability, clearance, volume of distribution, and half-life. 
AUC from zero to time t of sample collection can be obtained by 
planimetry, the 'cut and weigh' method, and most commonly by the trapezoidal 
rule. The area beyond the last concentration (C*) data point (time t*) of the post-
absorption phase is obtained from: 
Area from t* to oo = C*/k .[7] 
where k is the first order elimination constant. When this area is added to the 
AUC from zero to time t, the total AUC is obtained. The ratio of total AUC 
obtained after oral dosing (AUCp o ) to that obtained after intravenous dosing 
(AUCj v ) is a measure of the fraction of the drug amount that reaches the systemic 
circulation or bioavailability (F). 
F = AUCP.O./AUCLV."""". •••••••.[8] 
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Therefore, bioavailability is a ratio of the zero moment after oral dose to that after 
intravenous dose. 
AUC from zero to time t is referred to as the area under the first moment 
curve (AUMC). The ratio of AUMC to total AUG is a measure of its mean 
residence time (MRT), a time by which over 60% of administered dose is 
eliminated from the body. MRT, like half-life, is a function of volume of 
distribution and clearance. It may provide information on mean absorption time for 
a drug. 
By statistical moment theory, volume of distribution at steady state (Vss), 
after intravenous bolus dose of a drug, can be determined independent of the drug 
elimination processes as: 
Vdss = D L V ; A U M C / ( A U C ) 2 [9] 
Therefore, volume of distribution at steady state is a product of dose and ratio of 
the first moment to the square of the zero moment. 
It is known that total clearance of a drug from plasma equals to the ratio 
of overall elimination rates (i.e. sum of elimination processes occurring in all 
organs) of the drug to drug concentration in the plasma. This ratio was found to 
be equal to the value obtained from expression: 
29 
CLp = Doseiv./AUC 苕 ........[10] 
Therefore, clearance can be obtained by dividing dose given by the zero moment. 
During constant or chronic frequent dosing, clearance of a drug at steady 
state can be obtained by: 
CLp = R0/Css•.……… [11] 
where Rq is dosing rate and Css is concentration at steady state. 
It is noted that if the drugs are completely and rapidly absorbed after oral 
administration, oral dose may be approximated to intravenous dose during the 
calculations. 
1.4.4 Pharmacokinetic Parameters 
1.4.4.1 Clearance 
Clearance is a measure of efficiency of irreversible elimination of a drug 
from the body and is a determinant of maintenance dose rate required to achieve 
a desired concentration or effect, if metabolites are inactive, at steady state. 
Clearance concepts are more useful than half-life estimations for understanding 
drug elimination because the value of clearance is directly controlled and 
30 
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CL = F _ / C [12] 
and, 
CL = Ro/Css.. ……"…….：113] 
where Cavss is the average steady state drug concentration in plasma during multiple 
dosing, and Css is steady state drug concentration in plasma during constant rate 
infusion. F is bioavailability; D is the dose; y is dosing interval; Ro is constant 
infusion rate and CL is total systemic clearance of the drug. Therefore, clearance 
is measured in volume per unit time. 
Total systemic clearance for drug (CL = dose/AUC) is a sum of renal and 
non-renal clearance contributions. While there are a number of organs (e.g. lungs) 
which might conceivably contribute to the non-renal clearance of a drug, for most 
drugs, the liver appears to be the predominant site. Therefore, substraction of 
renal clearance (CLr； which is the only individual organ clearance that can easily 
be directly measured), from total systemic clearance yields an estimate of hepatic 
clearance (CLh). Hepatic clearance may be due to drug metabolism and/or biliary 
excretion. 
31 
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1.4.4.2 Volume of Distribution 
Volume of distribution is a relationship between concentration of a drug in 
plasma to total amount of drug in the body. It is a determinant of the size of 
loading dose if steady state concentration is to be achieved quickly. At equilibrium, 
only the unbound fraction of drug concentration (fu) can enter and leave the 
tissues, and concentration of the unbound drug in plasma and tissues is the same. 
Therefore, total amount of a drug in the body can be expressed as: 
Vd.C = Vdp.C + Vdt.Ct.“." [14] 
where Vd is the total volume of distribution; Vdp is plasma volume of distribution; 
Vt is apparent volume of all tissues; C is plasma concentration of the drug and Q 
is concentration of the drug in tissues. After a series of substitutions equation 14 
becomes: 
Vd = Vdp + fu/fut-Vdt [15] 
where fut is the total fraction in tiissues. Therefore, volume of distribution increases 
with increases in physical or anatomical volumes or tissues binding and with 
decreases in plasma protein binding. The volume of distribution of a drug that is 
unbound in the body is equal to either total body water (e.g. antipyrine) or 
extracellular fluid volume e.g. (bromide ion), because fu/fut = 1. Besides, when 
a drug is more extensively bound to plasma proteins than to tissue components 
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(e.g. warfarin) (i.e. fu/fut is very small), volume of distribution for the drug will 
be relatively small. However, when a drug is avidly bound to tissue components 
than plasma proteins (i.e. fu/fut is very large), volume of distribution of the drug 
will be large. For drugs with volume of distribution over 100 litres, Vdp becomes 
negligible such that changes in fu and ‘ can lead to proportional direct or inverse 
changes in Vd (equation 15). 
• � 
1.4.4.3 Half-life 
Half-life (TVi) is the time taken for total amount of drug in the body to fall 
by half. It is a determinant of duration of action of a drug after single dose 
administration and time to reach steady state with chronic dosing and frequency 
of dosing. It takes 3 to 5 half-lives of a drug to reach 75 to 97% of the eventual 
steady state concentration, and the more frequent a drug is given the less 
fluctuation in steady state concentration. Half-life is a secondary pharmacokinetic 
parameter. It is determined by volume of distribution (Vd) and clearance (CL). 
m = 0.693. Vd/CL [16} 
Half-life can be used to determine amount of drug remaining in the body after 
dosing: 
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where Q is fraction of the dose remaining after a drug, and n is number of half-
lives at that particular time after dosing. 
1.4,4.4 Bioavailability 
Bioavailability (F) is a measure of the fraction of a drug that reaches the 
systemic circulation after administration. When a drug is completely absorbed after 
oral administration and there is no appreciable gut metabolism, then the major 
determinant of its bioavailability is presystemic metabolism (first pass effect) by 
the liver. First pass elimination is determined by the hepatic extraction ratio for 
a drug. Thus, the fraction of dose removed is equal to the hepatic extraction ratio 
(ER) such that the fraction escaping to the systemic circulation is (1 - ER). 
Therefore, significant first pass effect will occur for drugs with a high hepatic 
extract ratio, e.g. lignocaine (Boyes et aL, 1971) and propranolol (Shand and 
Rangno, 1972)，but not with poorly extracted drugs like antipyrine, tolbutamide 
and warfarin (Anderson and Vesse, 1974). 
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CHAPTER 2 
The Effects of Danshen (Salvia miltiorrhiza) on Pharmacokinetics and 
Pharmacodynamics of Warfarin 
2.1 Introduction 
2.1.1 Danshen 
Danshen is the root of Saliva miltiorrhiza Bge, According to concepts in 
traditional Chinese Medicine (TCM), Danshen is claimed to be nontoxic and has 
a bitter taste and a slightly "cold" (yin) property. Blood-stimulating, 
anticoagulating, sedative, tranquillizing, anticarbuncular and analgesic actions are 
other properties attributed to Danshen (Lei, 1986). In some places in China, the 
roots of Salvia przewalskii Maxim, Salvia trijugdiDiels, Salvia miltiorrhiza Bge zxt 
also used as substitutes for Danshen while the stems and leaves of these plants are 
used as medicine for other purposes (Chang and But, 1986). 
Danshen has been a drug of choice for treating cardiovascular 
abnormalities, (e.g. angina pectoris and myocardial infarction) in China for many 
years (Liu, 1983) . Although Danshen has been used for thousands of years in the 
Far East, its medical efficacies are based on clinical experience rather than on 
experimental studies. As a result, the value of Danshen is not recognized in 
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Western medicine. A considerable amount of clinical and experimental studies 
have been performed to assess its efficacy in cardiovascular diseases (Lei and 
Chiou, 1986; Qian et al. ,1978). The results showed that Danshen relieved angina 
pectoris and myocardial infarction. Danshen is now used routinely in Eastern 
China provinces, for relieving acute episodes of angina pectoris and myocardial 
infarction as well as for the prophylaxis of angina in patients. 
The use of Danshen by modern western physicians can be traced back to 
the 1960s. The western physicians found that traditional Chinese doctors 
prescribed Danshen for relieving chestpain attacks in patients whose symptoms and 
signs are similar to angina pectoris of various clinical subtypes. With the assistance 
of chemical extraction work, the main success at the time was the introduction of 
intravenous preparations of Danshen for clinical trials. Therefore, it was possible 
for physicians to observe the therapeutic effects of intravenous Danshen extracts 
in acute patients and in experimental studies with laboratory animals. 
Due to historical reasons, clinical experiments on Danshen could not be 
done at that time when methods in clinical pharmacology were lacking in China. 
Within this decade, clinical use of Danshen, through integration of Chinese and 
Western Medicinal theories, have been extended to other diseases such as 
ischaemic cerebral stroke and thromboembolic-angiolitis, chronic liver diseases 
such as hepatitis and early cirrhosis, lupus erythromatosis, chronic pneumonia, and 
some dermatoses such as psoriasis. 
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2.1.2 Chemical Composition of Danshen 
The root of Salvia miltiorrhiza contains tanshinones I, IIA and IIB, 
isotanshinones I and II, cryptotanshinone, isocryptotanshinone, methyltanshinonate, 
hydroxytanshinone IIA, miltirone, 1-dihydrotanshinone I, salviol, protocatechuic 
aldehyde, protacatechuic acid, B-(3,4-dihydroxyphenyl)lactic acid, and vitamin E 
(Tang and Eisenbrand, 1992). The chemical structures of tanshinone I , tanshinone 
II, cryptotanshinone and miltirone are shown in Figure 2.1. 
2.1.3 Pharmacological Action 
The pharmacological actions of Danshen can be summarized under the 
following headings: 
(1) Actions on Coronary Circulation: 
Intravenous infusion of Danshen root extract to anaesthetized cats 
significantly increased coronary blood flow and lowered coronary resistance, but 
increased myocardial oxygen consumption (Chen, 1981). j8-(3,4-dihydroxyphenyl)-
lactic acid dilated the coronary muscle of pig and antagonized its morphine- or 
propranolol-elicited contraction, while tanshinone IIA sodium sulfonate and 
protocatechuic aldehyde significantly constricted the isolated coronary vessels 
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Figure 2.1 Chemical structures of tanshionone I, tanshinone II， 
cryptotanshinone and miltirone ^ 
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(2) Actions on Myocardial Ischaemia and Infarction 
The. electrocardiogram (ECG) abnormalities in rabbits with acute 
myocardial ischaemia induced by pituitrin were improved or counteracted by 
treatment with Danshen root decoction, Danshen root extract injection or /3-(3,4-
dihydroxyphenyl)-lactic acid (Wang et al.f 1980). The Danshen root extract 
injection also promoted the regeneration of myocardial cells in the infarcted areas, 
and reduced the damage to the intercalated disk of the ischaemic myocardium (Liu, 
1983). 
(3) Actions on Blood Pressure and Peripheral Blood Vessels 
The hypotensive effect due to a decrease in cardiac output was 
demonstrated in rabbits by the intravenous injection of Danshen root decoction or 
extract (Lei and Chiou, 1986). Tanshinone IIA sodium sulfonate caused a slight 
increase in blood pressure (Ke, 1982). 
(4) Actions on the Heart 
In the isolated rabbit heart, Danshen root extract injection decreased the 
heart rate and transiently decreased the cardiac contractility (Lei and Chiou, 1986). 
Tanshinone IIA sodium sulfonate had a dose-dependent inhibitory effect on the 
contractility of the isolated rabbit heart. However, only a mild increase in the 
contractility of the rat hearts m vitro was observed (Liu, 1983). 
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(5) Actions on Blood Coagulation and Platelet Aggregation 
Previous studies have shown that Danshen root extract injection in rabbits 
prolonged prothrombin time, thrombin time, and continuous thrombin time and 
showed positive changes in the partial thromboplastin time (PPT) test, indicating 
the presence of anticoagulating action (Chinese Cooperative Group for the 
Research of Chinese Drugs, 1975). Human platelet aggregation induced by 
adrenaline was inhibited by Danshen root decoctipn. This action was probably 
related to its fibrinolytic activity producing the fibrin-fibrinogen degradation 
• 0 
products (FDP) which in turn inhibited platelet aggregation (Yuan and Jiang, 
1984). Tanshinone IIA sodium sulfonate inhibited adenosine diphosphate(ADP)-
induced platelet aggregation in coronary patients (Ke, 1982) 
(6) Actions on the Central Nervous System 
The Danshen root extract injection reduced the spontaneous activity of mice 
and potentiate the hypnotic action of chlorpromazine, chloral hydrate, amobarbital 
sodium, and cyclobaxbital sodium in mice (Chen et al., 1979). The Danshen root 
extract injection in rabbits caused a reduction in the spontaneous electrical activity 
of the cerebral cortex, an increase in the late action potential threshold after 
repeated stimulation, and an increase in the induced action potential of sensory 
stimulation (Chen et al” 1979). These results suggested that the inhibitory action 
of the Danshen root extract injection on the central nervous system was the 
rationale behind its quick-acting effects in the treatment of coronary disease (Chen 
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et al, 1979; Yuen and Jiang, 1984). 
(7) Miscellaneous Actions 
In vitro bacteriostatic studies of the 1:1 decoction of Danshen roots showed 
that it was inhibitory against Staphylococcus aureus, Escherichia coli, Proteus 
vulgaris, Shigella flexneri and Salmonella typhi (Liu, 1983). 
Intramuscular injection of Danshen root decoction to mice markedly 
increased the macrophage activity in chicken erythrocytes (Ke, 1982). The 
Danshen root extract injection increased T lymphocytes in chronic bronchitis 
complicated with pulmonary heart disease, as well as in asthmatic bronchitis and 
in chronic bronchitis associated with pulmonary emphysema (Ke, 1982). 
2.1.4 Aims 
Traditional Chinese medicine claims popularity with our community as an 
effective form of health and medical care. Many people often add TCM as 
ingredients for cooking. Moreover, many people use TCM as an alternative 
medical treatment or even co-administered with western medical treatment 
(WPCMIR, 1991). Hence, the risk of drug interactions between TCM and western 
drugs may occur. Besides, It has been observed that patients who were on routine ^ 
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Danshen is a common example of herbal medicine which is freely available 
as proprietary TCM preparations in Hong Kong and in China. In this chapter, 
Danshen is used to investigate the potential drug-drug interactions on the 
pharmacokinetics and pharmacodynamics of warfarin in rats. The study was 
divided into a single dose study and a steady state study. In the single dose study, 
the animals were treated with a single dose of warfarin alone or after treatment 
with Danshen extract. In the steady state study, the animals were administered with 
warfarin daily to reach steady state and then they were treated with Danshen 
extract for three days. 
2.2 Materials and Methods 
2,2.1 Chemicals and reagents 
Warfarin was purchased from Sigma Chemical Co. (St Louis, MO, 
U.S.A.). Acenocoumarol was supplied as gift (Ciba-Geigy, Basle, Switzerland). 
Methanol (HPLC grade) was purchased from Mallinckrodt Speciality Chemical Co 
(Paris, KY, U.S.A.). Diethyl ether was obtained from E. Merck (Darmstadt, 
Germany). Hydrochloric acid (2M) was washed with diethyl ether, and water was 
double-distilled before use. The thromboplastin reagent, Simplastin, was supplied 
from Organon Teknika Corporation. (Durham, NC, U.S.A.). Danshen roots 
(Picture 2.1) were purchased from Hip Hing Lung Chinese Medicine Store (Hong 
Kong) and authenticated. The commercial Danshen extract powder (Picture 2.2) 
was supplied as a gift from Winsor Health Products Ltd. (Hong Kong) 
42 
_ 
Picture 2.1 Danshen {Salvia Miltiorrhiza) Roots 
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Picture 2.2 Commercial Danshen Extract Powder (in capsule form) 
44 
2.2.2 Preparation of Danshen aqueous extract 
Danshen was authenticated pharmacognostically by the Chinese Medicinal 
Material Research Center (CMMRG) of the Chinese University of Hong Kong. 
The Danshen root (1 kg) was first cut into small pieces (Picture 2.1), and soaked 
in double-distilled water (3 L) overnight at room temperature. A further 400 ml 
double-distilled water was added and boiled for an hour on the next day. The 
solution was then filtered by a double-layer bandage. The filtrate was collected and 
left overnight at room temperature. The supernatant was then pipetted off and the 
precipitate was filtered once again through filter paper (15 cm, Qualitative Grade 
1’ Whatman, France). The filtrate was added into the supernatant solution. The 
whole solution was concentrated by a rotatory evaporator below 60°C under 
vacuum. The residue was re-dissolved in water to make up to approximately 2 g 
dried weight of Danshen per ml (500 ml). The Danshen extract solution was stored 
at -4°C and then thawed before use. 
2.2.3 Treatments 
2.2.3.1 Animals and Sampling Method 
Male Sprague Dawley rats weighing 250 - 300 g were used. Animals were 
allowed free assess to a standard diet and tap water. The animals were fasted 




Blood sample (0.6 ml) was collected from the tail artery. The freshly drawn 
blood was mixed thoroughly with sodium citrate (3.8%) in a ratio of 9:1 (60 /il). 
After centrifugation for 10 min. at 3000xg, the plasma was collected for High 
Performance Liquid Chromatography (HPLC) and prothrombin time (PT) 
measurements. 
Pharmacokinetic study : The animals (N=10) were treated with Danshen extract 
(5 g/kg, dose volume二0.75 ml) intraperitoneally twice daily. Physiological saline 
was used instead of Danshen extract in the control group. After three days of 
treatment with Danshen extract, a single oral dose (2 mg/kg, dose volume=0.3 
ml) of warfarin was administered. Blood samples (0.6 ml) were collected at 0, 2, 
4, 8, 12, 24, 36 and 48 hours post dose. The plasma was separated by 
centrifugation (10 min. at 3000xg) and stored at -20°C before HPLC analysis. 
Pharmacodynamic study : The treatment was similar to that in pharmacokinetic 
study and the same doses of Danshen extract and warfarin were used. In this case, 
the blood samples (0.6 ml) were collected daily at the same time in the morning 
during the Danshen treating period and after an oral administration of warfarin. 
The plasma was separated by centrifugation (10 min. at 3000xg) and used for 
determination of prothrombin time (PT). 
Steady State Study : The animals (N=12) were divided into two groups. Both 
groups were administered warfarin orally (0.2 mg/kg/day, dose volume=0.3 ml) 
daily to maintain a steady state. After five days of warfarin treatment, the steady 
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state was reached and maintained. One group was treated with Danshen extract (2 
g/kg, dose volume=0 3 ml) orally twice daily for three days while warfarin were 
also administered daily (0.2 mg/kg/day, dose volume=0.3 ml). The other group 
was treated with Commercial Danshen extract (1 g/kg, dose volume=0.3 ml) 
orally twice daily for three days with concurrent warfarin treatment. To avoid the 
possible interaction of warfarin and the Danshen extract in the stomach, the 
extracts were administered 4 hours after the administration of warfarin. Blood 
samples (0.6 ml) were collected daily and the plasma was then separated by 
centrifugation for PT measurement and stored at -20°C before HPLC analysis. 
2.2.4. High Performance Liquid Chromatography 
The high performance liquid chromatography system consisted of a Hewlett 
Packard (HP) 1050 series pumping system and multiple wavelength detector 
(Waldbronn, Germany), a Model 7125 syringe loading sample injector with a 200 
fx\ loop (Rheodyne Incorporated, Cotati, CA, U.S.A.) and a Model L6512 chart 
recorder (Linseis, Germany). The eluates were analyzed by passing through a 
Hiber pre-column (50 mm x 4.6 mm I.D. packed with Perisorb RP-8 30 /xm C18 
reverse phase) which were obtained from E. Merck (Darmstadt, Germany), and 
a Waters /iBondapak C18 analytical column (8 mm x 10 cm I.D.) which was 
purchased from Waters (Milford, MA, U.S.A.). 
c • ., “ . ‘ 
The operation' conditions for the HPLC system were: mobile phase, 
consisting of 65% methanol with 10 mM phosphate buffer at pH 5.7 which was 
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filtered through a 0.22 恥m filter and simultaneously degassed under vacuum; flow 
rate, 1.5 ml/min; temperature, ambient (25 土 10C); multiple wavelength detector, 
X=215 nm. During the assay, the mobile phase was recycled. Under these 
conditions, good separation of warfarin and acenocourmarol (internal standard) was 
achieved with respective retention times of 10 and 15 min. (Figure 2.2) 
All the glassware was cleaned by soaking overnight in a 2.5% solution of 
Extran (E. Merck, Darmstadt, Germany) in water, then thoroughly rinsed with 
methanol, hot tap water and distilled water. The tubes were subsequently silanised 
by rinsing with 3% hexamethyldisilazane (HMDS) in chloroform, and dried at 
150°C overnight in oven. 
2.2.4.1 Standard Solutions 
Stock solutions of warfarin and acenocoumarol (100 fig/ml) in methanol 
were prepared and stored frozen as aliquots (1 ml) at -20°C. Standard solutions 
of 10 fig/m\ warfarin and 12 ^ g/ml acenocoumarol were prepared and kept at 4 � C . 
Standard solutions were prepared freshly every two weeks. 
2.2.4.2 General assay procedures 
The plasma warfarin concentration was determined by a modification of a 
HPLC method (Ghan and Woo, 1988). A quantity of acenocourmarol (300 ng in 
25 in methanol), the internal standard, was added to 0.2 ml drug-containing 
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Figure 2.2 Representative chromatogram demonstrating the HPLC 
separation of warfarin (a) and acenocoumarol (b) in a plasma 
‘sample. 
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plasma in a 10 ml-glass centrifuge. Methanol (300 /xl) was added to precipitate the 
plasma protein, followed by 1.5 ml double-distilled water and 0.5 ml 2M 
hydrochloric acid. Diethyl ether (7 ml) was added for extraction. The solution was 
then mixed with the aid of an automatic shaker for 15 mini, and subsequently 
, � t * _ \ 
centrifuged for 15 min. at 3000xg to break the emulsion. Only the ethereal extract 
was collected and transferred into a 15 ml-evaporation tube with tapered base. The 
extract was evaporated to dryness at 45°C under nitrogen in a water bath. The dry 
residue was then dissolved in 50 fil methanol. An 25 ftl aliquot was injected into 
the HPLC system. The detection limit of the assay was 3.3 ng/ml. The inter-batch 
assay at 1.25 /xg/ml was reproducible and precise with coefficient of variation of 
7.7%. 
2.2.4.3 Calibration curve 
Calibration curves of peak height ratios to concentration were linear over 
the range of 250 - 3750 ng/ml for plasma warfarin. 
Calibration by adding known amounts of warfarin (50 ng - 750 ng) was 
added to plasma, together with the internal standard (acenocoumarol) (300 ng). 
The plasma was taken through the entire sample preparation procedure. The 
linearity of the peak height ratios to concentration was tested by linear regression 
analysis. The calibration curve is shown in Figure 2.3. The correlation coefficient 
of linearity (r) is 0.999. 
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To assess the recovery of warfarin from plasma samples using the 
extraction procedure, the drug was added to drug-free plasma at 1 /ig/ml and 
assayed with the internal standard. For comparison, the same concentration of 
warfarin and internal standard were prepared in methanol, evaporated and assayed 
with the extraction step omitted. The corresponding peak height ratios were then 
compared. This was about 87% throughout the investigation. 
The intra-assay differences were assessed by the response of a standard 
solution at the beginning and at the end of the assay. The differences were less 
than 8 % (n=10). 
2.2.5 Prothrombin time measurement 
The apparatus used in prothrombin time (PT) test include a Coagulometer 
KC 4A with CR-A computer, and stainless steel balls (no. Z03200), plastic tubes 
(no. 834011) and glass tubes (15 mm I.D.) as accessories (Heinrich Amelung 
GmbH, Lehbrinksweg, Lemgo-l-Lieme, Germany). Other apparatus used included: 
10 ml capacity centrifuge tubes with well fitted, telfon-lined screw caps (Sovirel, 
Levallois-Perret, France), 15 ml capacity evaporation tubes with finely tapered 
bases. 
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2.2.5.1 Prothrombin Time (PT) Test 
The one-stage prothrombin time test was performed (Sawyer and Raasch, 
1984). Before the test, 4 ml of reconstituted Simplastin was prewarmed to 37°C. 
Drug-containing plasma (0.1 ml) was added to the plastic tube and incubated at 
37°C for 1 minute. Then 0.2 ml of the prewarmed Simplastin was added 
immediately and timing for clot detection was simultaneously noted. The clotting 
time was recorded in seconds. The test was duplicated in each sample to ensure 
accuracy 
2.2.6 Data Analysis 
The plasma concentration data were analyzed by a non-compartmental 
method. The principle of non-compartmental pharmacokinetic analysis has been 
briefly outlined in Chapter 1. The data was analyzed by a BASIC computer 
program, PKCALC (Shumaker, 1986), which performs standard statistical and 
pharmacokinetic analysis of multisubject data sets. The plasma warfarin 
concentration-time data associated with the terminal phase were evaluated by the 




2.2.7 Statistical analysis 
The data were analyzed by the unpaired Student's t-test in the single dose 
study and by the paired Students' t-test in the steady state study. A value was 
considered significantly different from the control value if it fell outside the 95% 
confidence limits (P < 0.05). 
2.3 Results 
2.3,1 Effects of Danshen on Pharmacokinetics of Warfarin 
The time courses for mean plasma concentrations of warfarin administered 
alone or after three day treatment of Danshen extract are shown in Figure 2.4. It 
was observed that the ntaximum plasma warfarin concentration was higher after 
the Danshen extract treatment (control: 5.5±1.6 /xg/ml; Danshen treated: 
11.0土4.0 fig/ml; P < 0.001). In the first 24 hours, the mean plasma warfarin 
concentrations after the Danshen treatment were also significantly higher than that 
in the control group (P <0.05 toP < 0.001). 
The pharmacokinetic parameters for warfarin are summarized in Table 2.1. 
The AUC 4o of the test group was significantly greater than that in the control 
group (control: 154.8±72.3 /ig-hr/ml; Danshen treated: 269.5 土90.8 pg.hr/ml; P 
< 0.005), but there was no difference in the total AUGq between two groups 
(control: 248.7土 134.7 ^g-hr/ml; Danshen treated: 311.3土 114.8 ^g-hr/ml). The 
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Cmax and Tmax were significantly increased (control: 5.5土 1.6 ftg/ml; 3.6土0.8 hr; 
Danshen treated: 11.0土4.0 /ig/ml; 7.2土 1.7 hr; P < 0.001; P < 0.001), while 
the TV2 and Ka were significantly decreased after the Danshen treatment (control: 
31:8土6.4 hr; 2.59土0.88; Danshen treated: 16.0土2.6 hr; 1.26土0.55; P < 0.001; 
P < 0.001). But there was no significant change in CL between the two groups 
(control: 3.53土2.40 ml/hr; Danshen treated: 2.23+0.98 ml/hr), while Vd was 
significantly decreased after the Danshen treatment (control: 142.5土75.2 ml; 
Danshen treated: 54.4土 18.9 ml; P < 0.005). 
s 
2.3.2 Effects of Danshen on Pharmacodynamics of Warfarin 
Figure 2.5 shows the time courses of mean prothrombin times (PT) after 
two doses of warfarin. The baseline PT values (from Day -3 to Day 0) were 
similar whether the rats were treated with Danshen extract or not. This suggested 
that the Danshen extract itself did not affect blood coagulation. In Day 1 and Day 
2, the PTs of the Danshen treated group were significantly increased and higher 
than the PTs of the control group after warfarin treatment (control: Day 1: 
41.1 士3.4 seconds; Day 2: 22.4+5.7 seconds; Danshen treated: Day 1: 49.9+4.2 
seconds; Day 2: 36.4士7.6 seconds; P < 0.001; P < 0.001). 
2.3.3 Effects of Danshen on the Steady State Study of Warfarin 
Figure 2.6 illustrates the time course of mean plasma concentrations of 







































































































































































































































































































































































































































































































































































































extract were given orally from Day 5 to Day 7. It was observed that the mean 
plasma warfarin concentrations in Day 7 (1.44 土0.23 pg/ml) and Day 8 
(1.69土0.11 jtig/ml) were significantly higher than that in Day 5 (0.93 土0.21 
ftg/ml) (P < 0.01; P < 0.01)) when the steady state of warfarin was maintained. \ , 
Figure 2.7 shows the time course of mean plasma concentrations of 
warfarin after daily administration in steady state study in rats while the 
Commercial Danshen powder extract was given orally from Day 5 to Day 7. The 
mean plasma warfarin concentrations in Day 6 (1.25 士0.17 ^g/ml; P < 0.05), 
Day 7 (1.53 土0.25 弘g/ml; P < 0.01) and Day 8 (1.60土0.19 /ig/ml; P < 0.01) 
were significantly higher compared with that in Day 5 (1.07土0.16 /xg/ml). 
Figure 2.8 shows the time courses of mean plasma concentrations of 
warfarin administered daily in steady state study before and after separate Danshen 
extract and Commercial Danshen extract powder treatments. There was no 
significant difference in the mean plasma warfarin concentration over the whole 
time course between the two groups (Danshen treated: Day 5: 0.93+0.21 ftg/ml; 
Day 6: 1.05土0.31 弘g/ml; Day 7: 1.44土0.23 pg/ml; Day 8: 1.69土0.11 pg/ml; 
Commercial Danshen treated: Day 5:1.07±0.16/ig/ml;Day6:1.25 土0.17pg/ml; 
Day 7: 1.53土0.25 pg/ml; Day 8: 1.60土0.19 ^g/ml) 
Figure 2.9 illustrates the time courses of mean prothrombin times after 
daily administration of warfarin to rats in steady state study before and after giving 




























































































































































































































































































































































































































































































































































































































































































































there were no significant change in PT from Day 6 to Day 8 (Danshen treated: 
Day 6: 13.1 土 1.9 seconds; Day 7: 13.4土 1.8 seconds; Day 8: 13.9土 1.8 seconds; 
Commercial Danshen treated: Day 6: 12.5土 1.0 seconds; Day 7: 13.3±2.2 
seconds; Day 8: 13.1 土 1.2 seconds) compared with Day 5 (Danshen treated: 
12.7土 1.5 seconds; Commercial Danshen treated: 12.5土 1.3 seconds) when the 
steady state of warfarin was maintained. 
2.4 Discussion 
The single dose study in rats showed some evidence of pharmacokinetic and 
pharmacodynamic interactions between warfarin and Danshen extract, while the 
steady state study only showed the pharmacokinetic interactions between warfarin 
and Danshen extract. Significant alterations were observed after three days 
treatment of Danshen extract either in the plasma concentration-time profile of 
warfarin or on the prolongation of prothrombin time which was due to the possible 
inhibition of the vitamin K-dependent carboxylation of coagulation factors II, VII, 
IX and X (Park, 1988). In particular, the significantly higher AUC 4 q of warfarin 
indicated that Danshen extract would increase the initial bioavailability of warfarin 
(Table 2.1). There was no significant difference between the control and test 
groups in the total AUC q of warfarin. The Cmax for warfarin was increased in the 
Danshen treated group and the plasma warfarin concentrations in this group were 
only significantly higher than that of the control group over the initial 24 hours 
post dose period (Figure 2.4). This showed that Danshen extract would only affect 
the warfarin bioavailability. Since there was no significant change in the clearance 
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(CL), the shortening of elimination half-life (JV2) in the Danshen treated group 
was due to possibly a fall in volume of distribution (Vd). The fall in Vd cannot be 
explained at present, one possibility is that Danshen might inhibit warfarin uptake 
into liver. Warfarin hepatic uptake and hepatic metabolism have been shown to be 
governed by distinct processes such as metabolized by cytochrome P-450 system 
and extracted warfarin from hepatic portal vein into the liver cells in the rat 
(Covell, 1983). It means that the rate of warfarin uptake in the liver is different 
from the rate of metabolism of warfarin in liver. 
In our pharmacodynamic study, there was no significant change in PT 
during the Danshen treatment period between the two groups (Figure 2.5) showing 
that Danshen extract did not have any anticoagulating effect. Thus this observation 
was contradictory to those previously reported studies (Chang, 1986) which 
showed that Danshen could prolong the prothrombin time in rabbits. Significant 
increases in PTs (Day 1 and Day 2) were observed after a single dose of warfarin 
administration in the Danshen treated group (Figure 2.5). This observation could 
be related the pharmacokinetic results which the AUC4q of the Danshen treated 
group was significantly higher. One of the reasons of increasing warfarin 
bioavailability may be due to the possible drug-displacement effect. The previous 
study showed that aspirin may enhance the hypoprothrombinemic action of 
warfarin by displacing warfarin from plasma protein (Sandercock and Dunbabin, 
1991). Since aspirin alters the structure of the plasma protein (Hawkins, 1969). 
Therefore, aspirin may either displace warfarin or prevent it from binding with the 




there was no evidence to show that Danshen can displace warfarin from plasma 
protein. It was also observed that the effect of Danshen on pharmacodynamic 
interaction subsequently subsided and the PT returned to normal on Day 3 and Day 
4. This result showed that the effect of Danshen extract on the pharmacodynamics 
of warfarin is effective for two days after administration. 
Results of the steady state study could be interpreted under two aspects, in 
terms of pharmacokinetics and pharmacodynamics. In the pharmacokinetic study, 
the plasma warfarin concentrations in rats after treatment with Danshen extract or 
Commercial Danshen powder extract were significant increased. However, 
pharmacodynamically, both Danshen extracts did not affect the PT at warfarin 
steady state after the treatment (Figure 2.9). The results suggested that Danshen 
extract treatment increased plasma warfarin concentrations at steady state but no 
pharmacodynamic effect was observed. The two Danshen extracts did not show 
any significant difference in two aspects (Figure 2.9). There is no direct 
relationship between plasma warfarin concentration and prothrombin time 
measurement, because the measured PT reflects a balance between the rate of 
clotting factors synthesis and the rate of clotting factors degradation (Choonara et 
al.，1985). Warfarin affects only the rate of clotting factors synthesis which can 
be calculated from a knowledge of the PT and by making an assumption regarding 
the rate of clotting factors degradation (Nagashima et al” 1969; Choonara et al., 
1985). Thus, although the plasma warfarin concentrations were significantly 
increased, the PTs were not significantly altered which may probably due to the 
decrease in the rate of clotting factors degradation. 
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According to this study, there was some evidence to show the 
pharmacokinetic and pharmacodynamic interactions between Danshen and warfarin 
after a single dose warfarin administration. However, there was no 
pharmacodynamic interactions in the steady state study, while the plasma warfarin 
concentrations were significantly increased after the Danshen extract treatment. 
In conclusion, the mechanisms involved in the pharmacokinetic and 
pharmacodynamic interactions between warfarin and Danshen could not be clearly 
identified from the observation in this study. Further investigations are required 
to explore the mechanisms of the interactions. Since warfarin has two 
stereoisomers, R- and S-warfarin, which are metabolized by different pathways in 
liver (Lewis et al” 1974; Hewick et al” 1975), R- and S-warfarin metabolism 
after the Danshen extract treatment can be investigated to get more evidence in the 
interactions. Moreover, Danshen extract contains a variety of different active 
ingredients, e.g. tanshinone, isotanshinone (Tang and Eisenbrand, 1992). Study of 
these active ingredients in Danshen extract with warfarin can be used for further 
analysis of the interactions. Nevertheless, the result of this study suggests that the 
interaction between crude Danshen extract and warfarin is clinically important and 
could occur in patients who have been stabilized with warfarin treatment on self-





Effects of Danshen (Salvia miltiorrhiza) on Pharmacological Properties of the 
Stereoisomers of Warfarin 
3.1 Introduction 
There are many examples of combinations of therapeutic agents, such as 
diuretics with antihypertensives (Ariens and Wuis, 1987). Besides these composite 
preparations, 25% of all therapeutic agents are incidentally mixtures, mainly 
racemates, reflecting the asymmetric structure of a large number of drug 
molecules, in most cases due to the presence of one or more chiral centres in the 
molecule (Ariens and Wuis, 1987; Ariens et al” 1989). As a result of the 
difference of biological systems and environments, the enantiomers of biologically 
active compounds often differ largely in their contribution to the desired and 
undesired action and in their pharmacokinetics (Drayer, 1986). 
In contrast to chiral drugs of natural origin which usually contain only one 
of two enantiomers, chemical synthesis generally results in the formation of both 
enantiomers unless stereospecific drug synthesis is employed. Stereoisomers 
contained in racemic drug preparations quite often exhibit pronounced quantitative 
differences in their pharmacological and toxicological properties (Drayer, 1986). 
In addition to the stereoselectivity of drug action, various aspects of drug 
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disposition also exhibit stereoselective drug metabolism in man and its therapeutic 
consequences have been appreciated (Aliens et al.9 1989). In view of the 
pronounced differences in activity and toxicity as well as the different 
pharmacokinetic behaviour of stereoisomers, one is administering in fact two drugs 
when giving a racemate. However, most physicians are not aware of this fact 
(Eichelbaum, 1988). 
3.1.1 Stereochemical Considerations of Drug Interactions on Warfarin 
Stereoselective drug metabolism may have important therapeutic 
implications in the case of drug interactions if pronounced differences in potency 
exist between enantiomers and their disposition is differently affected by the 
causative drug (O'Reilly et alf 1980;Toon et al 1986). 
Warfarin is a good example to illustrate the importance of studying the 
enantiomeric disposition of drugs, which exists as distinct stereoisomers, in drug 
interactions. The general pharmacological properties of warfarin have been 
mentioned in Chapter 1. O'Reilly et al (1980) elucidated the mechanism 
responsible for the augmented hypoprothrombinema of warfarin caused by the 
coadministration of phenylbutazone. They observed that although total warfarin 
plasma concentrations decreased during phenylbutazone treatment, the 
pharmacodynamic response of warfarin was augmented. In order to evduate 
whether or not phenylbutazone had a differential effect on the disposition of the 
more potent S-isomer, they studied the biological fate of the R- and S-enantiomers. 
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During phenylbutazone treatment, a highly significant increase in the plasma 
clearance of R-warfarin and significant decrease in the clearance of S-warfarin was 
observed compared with the administration of warfarin alone. Thus, 
phenylbutazone augmented the hypoprothrombinemic action of warfarin by 
inhibiting the metabolism of the more hypoprothrombinemic S-warfarin, and 
reduced total warfarin plasma warfarin plasma concentrations by greatly 
augmenting the clearance of R-warfarin. 
In 1986, Toon et al. investigated the warfarin-sulfinpyrazone interaction. 
An enhanced hypoprothrombinema was observed when warfarin and sulfinpyrazone 
were co-administered. This study illustrated even more the need of monitoring the 
individual enantiomers of racemic drugs. Whereas some of the subjects showed an 
increase in warfarin elimination T!/2, consistent with the enhanced pharmacologic 
response, other subjects showed a 25% decrease in warfarin elimination TV2, a 
result seemingly in contradiction with the observed enhanced pharmacologic 
response. Based on these data alone, conclusions regarding plasma concentration 
response relationships are meaningless. Therefore, the TV2 for the individual 
enantiomer should be considered. In one subject, the TV2 of S-warfarin increased 
from 25 to 49.5 hr, while that of the R-enantiomer decreased from 46 to 38 hr 
with sulfinpyrazone dosing. In another subject, the TV2 of S-warfarin increased 
from 49 to 58 hr while that of R-warfarin was so greatly decreased from 87 to 25 
hr with sulfinpyrazone dosing that the TV2 of total warfarin decreased relative to 
the control value. But in both cases, the increased S-warfarin concentrations were 
in agreement with the enhanced pharmacologic response. 
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For the above mentioned drug interactions of warfarin, it probably is a 
good idea for individual drug stereoisomer levels to be determined and correlated 
with effect to see if any extra clinical benefit is gained by this additional analytic 
step. 
3.1.2 Aims 
In Chapter 2, the effects of Danshen extract on pharmacokinetics and 
pharmacodynamics were studied. The results shows that the pharmacokinetic and 
pharmacodynamic interactions were observed between Danshen extract and 
racemic warfarin. Since warfarin have two stereoisomers which have different 
pharmacologic potency, it was decided to investigate further the effects of Danshen 
extract on the concentrations of the two stereoisomers and to observe the effect of 




3.2 Materials and Methods 
3.2.1 Chemicals and reagents 
Warfarin was purchased from Sigma Chemical Co. (St Louis, MO, 
U.S.A.). Acenocoumarol was supplied as gift (Ciba-Geigy, Basle, Switzerland). 
Methanol(HPLC grade), hexane (HPLC grade) and ethanol were purchased from 
Mallinckrodt Speciality Chemical Co. (Paris, KY, U.S.A.). Diethyl ether was 
obtained from E. Merk (Darmstadt, Germany). Hydrochloric acid (2M) was 
washed with diethyl ether, and water was double-distilled before use. The 
thromboplastin reagent, Simplastin, was supplied from Organon Teknika 
Corporation (Durham, NC, U.S.A.). Danshen roots were purchased from Hip 
Hing Lung Chinese Medicine Store (Hong Kong). The Danshen roots extract was 
prepared as outlined in Chapter 2. Quinine and quinidine were supplied from 
Sigma Chemical Co. (St Louis, MO, U.S.A.). 
3.2.2 Separation of Stereoisomers of Warfarin and Acenocoumarol 
The R- and S-warfarin and R- and S-acenocoumarol were obtained by a 
modification of a chemical separation method (West, 1961). The procedures for 
the separation of the stereoisomers of warfarin and acenocoumarol were similar. 
The following procedure was outlined by using warfarin as an example. 
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3.2.2.1 Separation of S-warfarin 
A mixture of 100 ml chloroform and 150 ml acetone was mixed with 16.2 
g quinidine and 15.4 g of racemic warfarin. The solution was warmed at 60°C 
until all quinidine and warfarin powder were dissolved. Then, the solution was left 
overnight at ^20°C. The mixture was filtered and the filtrate (filtrate A) was 
collected for subsequent processing. The salt was dissolved in 150 ml acetone and 
left overnight at -20°C. The pure quinidine-S-warfarin salt was obtained. The salt 
was then dissolved into a solution of 50 ml 0.5M sodium hydroxide and 25 ml 
chloroform. The aqueous layer was added to excess hydrochloric acid and 4.2 g 
S-warfarin was collected. 
The S-warfarin salt was re-dissolved in 50 ml of a pre-warmed 80% 
aqueous acetone solution. After cooling to room temperature 1 g S-warfarin was 
obtained. After addition of 50 ml water was then added to the filtrate and cooling, 
second crop of 1.6 g S-warfarin was obtained. 
3.2.2.2 Separation of R-warfarin 
The filtrate A from above was concentrated to 50 ml by rotatory evaporator 
at below 60°C and then diluted with 50 acetone. Upon cooling overnight at -20°C, 
the salt was filtered and only the filtrate was collected. The filtrate was 
concentrated to dryness at 60°C under nitrogen in water bath. The dried residue 
was dissolved in 50 ml chloroform and extracted with 100 ml of 0.5M sodium 
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hydroxide. Addition of excess hydrochloric acid to the aqueous layer obtained the 
salt of partially resolved R-warfarin. The salt was then dissolved in a boiling 
solution of 6.7 g of quinine in 50 ml ethanol. The solution was cooled to room 
temperature and 150 ml of diethyl ether was added. The solution was left 
overnight at -20°C. Quinine-warfarin salt was collected by filtration at 4°C. This 
salt was recrystallized twice by dissolving in 50 ml ethanol and 50 ml diethyl ether 
and cooling at -20°C. After recrystallization, the pure quinine-R-warfarin was 
obtained. This salt was dissolved in a mixture of 50 ml chloroform and 50 ml 
0.5M sodium hydroxide. The R-warfarin was precipitated by the addition of excess 
hydrochloric acid into the aqueous layer. Re-crystallization at room temperature 
from 50% acetone yielded 1.6 g R-warfarin. 
3.2.3 Treatments 
3.2.3.1 Animals and Sampling Method 
Male Sprague Dawley rats weighing from 250 to 300 g were used/Animals 
were allowed free assess to a standard diet and tap water. The animals were fasted 
overnight before oral administration of warfarin and food was resumed 4 hours 
post dose. 
Blood sample (0.6 ml) was collected from the tail artery. The freshly drawn 
blood was mixed thoroughly with sodium citrate 3.8% in a ratio of 9:1(60 jul). 
After centrifugation for 10 min. at 3000xg, the plasma was collected for High 
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Performance Liquid Chromatography (HPLC) and prothrombin time (PT) 
measurements. 
Single Dose Study: As outlined in Chapter 2, the animals (N=10) were treated 
with a fixed dose (5 g/kg, dose volume=0.75 ml) of Danshen extract 
intraperitoneally twice daily. Physiological saline was used instead of Danshen 
extract in the control group. After three days of treatment with Danshen extract, 
a single oral dose (2 mg/kg, dose volume—0.3 ml) of warfarin was administered. 
Blood samples (0.6 ml) were collected at 0, 2, 4, 8, 12, 24，36, 48 and 72 hours 
post dose. The plasma was separated by centrifugation (10 min. at 3000xg) and 
stored at -20°C before HPLC analysis. 
Steady State Study: The treatment was to that outlined in Chapter 2. The animals 
(N=10) were treated warfarin orally (0.2 mg/kg/day, dose volume=0.3 ml) daily 
to maintain a steady state. After five days of warfarin treatment, the steady state 
was reached and maintained by measuring the prothrombin time (PT). The rats 
were treated with Danshen extract (2 g/kg, dose volume=0.3 ml) intraperitoneally 
twice daily for three days with concurrent warfarin treatment. Blood samples (0.6 
ml) were collected daily and the plasma was then separated by centrifugation (10 
min. at 3000xg) for PT measurement and stored at -20°C before HPLC analysis. 
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3.2.4. High Performance Liquid Chromatography 
The high performance liquid chromatography system consisted of a Hewlett 
Packard (HP) 1050 series pumping system and multiple wavelength detector 
(Waldbronn, Germany), a Model 7125 syringe loading sample injector with a 1000 
fil loop (Rheodyne Incorporated, Cotati, CA, U.S.A.) and a Model L6512 chart 
recorder (Linseis, Germany). The eluates were analyzed by passing through a 
Hiber pre-column (50 mm x 4.6 mm LD. packed with Perisorb RP-8 30 fim C18 
reverse phase) which was obtained from E. Merck (Darmstadt, Germany), and a 
Chiralcel OC analytical column (25 cm x 0.46 cm I.D.) which was purchased from 
Daicel Chemical Industries Ltd. (Tokyo, Japan). 
The operation conditions for the HPLC system were: mobile phase, 
consisting of hexane/ethanol (4:1 v/v) which was filtered through a 0.22 fim filter 
and simultaneously degassed under vacuum; flow rate, 1 ml/min; temperature, 
ambient (25 士 1�C); multiple wavelength detector, X=217 nm* During the assay, 
the mobile phase was recycled. Under these conditions, good separation of R-
warfarin, S-warfarin, R-acenocoumarol and S-acenocoumarol was achieved with 
respective retention times of 12, 18, 27 and 40 min. (Figure 3.1). 
All the glassware was cleaned by soaking overnight in a 2.5% solution of 
Extran (E. Merck, Darmstadt, Germany) in water, then thoroughly rinsed with 
methanol, hot tap water and distilled water: The tubes were subsequently silanised 
by rinsing with 3% hexamethyldisilazane (HMDS) in chloroform, and dried at 
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Figure 3.1 .A representative chromatogram demonstrating the HPLC 
separation of R-waifarin (a), S-warfarin (b), R-acenocourmarol (c) and S - . . 
acenocourmarol (d) in a plasma sample 
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150°C overnight in oven. 
3.2.4.1 Standard Solutions 
Stock solutions of racemic warfarin and racemic acenocoumarol (100 
fig/ml) in ethanol were prepared and stored frozen as aliquots (1 ml) at -20°C. 
Standard solutions of 20 fig/ml racemic warfarin and 20 ng/ml racemic 
acenocoumarol were prepared and kept at 4°C. Standard solutions were prepared 
freshly every two weeks. 
3.2.4.2 General assay procedures 
A quantity of racemic acenocoumarol (500 ng in 25 pel in ethanol) which 
was the chosen internal standard was added to 0.2 ml drug-containing plasma in 
a 10 ml-glass centrifuge tube. Methanol (300 /xl) was added to precipitate the 
plasma protein, followed by 1.5 ml double-distilled water and 0.5 ml 2M 
hydrochloric acid. Diethyl ether (7 ml) was added for extraction. The solution was 
then mixed with the aid of an automatic shaker for 15 min. and subsequently 
centrifuged for 15 min. at 3000xg to break the emulsion. Only the ethereal extract 
was collected and transferred into a 15 ml-evaporation tube with tapered base. The 
extract was evaporated to dryness at 45°C under nitrogen in a water bath. The 
dried residue was then dissolved in 80 fil ethanol. An 35 jul aliquot was injected 
into the HPLC. The detection limits of the assay on R-warfarin and S-warfarin 
were 8 and 4.8 ng/ml respectively. The inter-batch assay at 750 ng/ml R- and S-
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warfarin were reproducible and precise with coefficient of variation of 5% and 
8.3% respectively. 
3.2.4.3 Calibration curve 
Calibration curves of peak height ratios to concentration were linear over 
the range of 250 - 1250 ng ml"1 for both plasma R- and S-warfarin. 
Calibration was carried out by adding a known amount of warfarin (100 ng 
-500 ng) and the internal standard, acenocourmarol (500 ng), to drug-free plasma 
which was taken through the entire sample preparation procedure. The linearity of 
the peak height ratios to concentrations was tested by linear regression analysis. 
The calibration curves of R-warfarin and S-warfarin were shown in Figure 3.2 and 
Figure 3.3. The correlation coefficient of linearity (r) is 0.999 in R-warfarin 
calibration graph and is 0.998 in S-warfarin calibration graph. 
To assess the recovery of R- and S-warfarin from plasma samples by the 
extraction procedure, the drug was added to drug-free plasma at 750 ng/ml and 
assayed with the internal standard. For comparison, the same concentration of 
warfarin and internal standard were prepared in ethanol, evaporated and assayed 
with the extraction step omitted. The corresponding peak height ratios were then 
compared. The recoveries These were over 80% for both R- and S-warfarin 































































































































































































































































































































































































The intra-assay differences were accessed by the response of a standard 
solution at the beginning and at the end of the assay. The coefficients of variation 
� 
were less than 10% in both cases. 
3.2.5 Prothrombin time measurement 
The apparatus used in prothrombin time (PT) test was a Coagulometer KC 
4A with CR-A computer, and stainless steel balls (no. Z03200), plastic tubes (no. 
834011) and glass tubes (15 mm I.D.) as accessories (Heinrich Amelung GmbH, 
Lehbrinksweg, Lemgo-l-Lieme, Germany). Other apparatus used included: 10 ml 
capacity centrifuge tubes with well fitted, telfon-lined screw caps (Sovirel, 
Levallois-Perret, France), 15 ml capacity evaporation tubes with finely tapered 
bases. 
3.2.5.1 Prothrombin Time (PT) Test 
The one-stage prothrombin time test was performed throughout the whole 
period of investigation (Sawyer and Raasch, 1984). The procedure is same as 
described in Chapter 2. 
3.2.6 Data Analysis 
The plasma concentration data were analyzed by a non-compartmental 
method. The principle of non-compartmental pharmacokinetic analysis has been 
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outlined in Chapter 1. The data was analyzed by a BASIC computer program, 
PKCALC (Shumaker, 1986)，which performs standard statistical and 
pharmacokinetic analysis of multisubject data sets (Chapter 1). The plasma 
warfarin concentration-time data associated with the terminal phase were evaluated 
by the program for calculating the regression line using standard least squares 
t . 
linear regression techniques. 
3.2.7 Statistical Analysis 
The data were analyzed by the unpaired Students' t-test in the single dose 
study and by the paired Students' t-test in the steady state study. A value was 
considered significantly different from the control value if it fell outside the 95% 
confidence limits (P < 0.05). 
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3.3 Results 
3.3.1 The Effects of Danshen extract on the Single Dose Study 
The time courses for mean plasma R-warfarin and S-warfarin 
concentrations versus time in rats after oral administration of racemic warfarin 
alone are shown in Figure 3.4. It was observed that both R- and S-warfarin have 
similar maximum concentrations (R-warfarin: 3.4±0.6 /xg/ml; S-warfarin: 
3.4土0.3 /ig/ml). But, the plasma S-warfarin concentrations were significantly 
higher than that of R-warfarin from 8 to 72 hours (P < 0.05 to P < 0.005). 
Table 3.1 summarized the pharmacokinetic parameters of R- and S-warfarin after 
single oral dose of warfarin alone. The total AUC and TV2 of S-warfarin 
(115.2士24.5 pg.hr/ml; 23.6土4.6 hr) were significantly greater (P < 0.005; P < 
0.005) than those of R-warfarin (81.5土 16.8 ^g-hr/ml; 17.5土2.2 hr), while the 
clearance (CL) of S_warfarin (91.1 ±2.4 ml/hr) was significantly lower (P < 
0.005) than that in R-warfarin (12.8士3.1 ml/hr). There was no significant 
difference between R- and S-warfarin in the Cmax (R-warfarin: 3.4+0.6 /ig/ml; 
S-warfarin: 3.4土0.3 jtig/ml), Tmax (R-warfarin: 4.0±0.0hr; S-warfarin: 4.0土0.0 
hr), Vd (R-warfarin: 322.0土71.1 ml; S-warfarin: 301.9土23.7 ml) and Ka (R-
warfarin: 2.07士0.05; S-warfarin: 2.06土0.02). 
Figure 3.5 displays the time courses for mean plasma R- and S-warfarin 
concentrations in rats after single oral dose of racemic warfarin following three 
days treatment of Danshen extract. There was no significant difference in the mean 
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plasma concentrations between R- arid S-warfarin in the time courses except at 72 
hours post dose (R-warfarin: 0.9+0.4 ^g/ml; S-warfarin: 1.1 土0.3 /ng/ml; P < 
0.01). The pharmacokinetic parameters of R- and S-warfarin are summarized in 
Table 3.2. There was significantly greater TVz in S-warfarin (30.6士3.7 hr) 
compared with that of R-warfarin ¢5.5土4.8 hr) after the Danshen treatment (P 
< 0.005). No significant difference was found in the other pharmacokinetic 
parameters (Total AUC: R-warfarin: 223.1 土72.6 ftg.hr/ml; S-warfarin: 
236.4+63.5 ^g*hr/ml; Cmax: R-warfarin: 6.0土 1.2 fig/ml; S-warfarin: 5.5土0.9 
/Ltg/ml; Tmax: R-warfarin: 4.0士0.0 hr; S-warfarin: 4.0土0.0 hr; Vd: R-warfarin: 
179.8土45.3 ml; S-warfarin: 199.5±44.3 ml; CL: R-warfarin: 5.0土 1,8 ml/hr; S-
warfarin: 4.5±1.2 ml/hr; Ka: R-warfarin: 2.20土0.05; S-warfarin: 2.18土0.04). 
The time courses of mean plasma concentrations of R-warfarin in 2 groups 
of the rats after oral administration of racemic warfarin alone or after Danshen 
treatment are shown in Figure 3.6. It was observed that the plasma R-warfarin 
concentrations were significantly greater (P < 0.005) after the Danshen treatment 
than that of the control in the time courses. The pharmacokinetic parameters of R-
warfarin of the control group and the Danshen treated group are displayed in Table 
3.3. Both groups have the same Tmax (control: 4.0土0.0 hr: Danshen treated: 
4.0士0.0 hr), whiles the other parameters have significant differences. The total 
AUC (control: 81.5土 16.8 /xg-hr/ml; Danshen treated: 223.1+72.6 pg.hr/ml)， 
Cmax (control: 土0.6 fig/ml; Danshen treated: 6.0土 1.2 figfrnl), TVi (control: 
17.5土2.2 hr; Danshen treated: 25.5士4.8 hr) and Ka (control: 2.07+0.05; 
Danshen treated: 2.20土0.05) in the Danshen treated group were significantly 
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higher (P < 0.005) than that in the control group. Besides, significantly lower Vd 
(control: 322.0土71.1 ml; Danshen treated: 179.8土45.3 ml; P < 0.005) and CL 
(control: 12.8士3.1 ml/hr; Danshen treated: 5.0土 1.8 ml/hr; P < 0.005) were 
found in the Danshen treated group compared with those of the control group. 
Figure 3.7 shows the time courses of mean plasma S-warfarin 
concentrations in 2 groups of the rats after single oral dose of racemic warfarin 
alone or after the Danshen treatment. Similar to R-warfarin, the mean plasma 
concentrations of S-warfarin were significantly greater (P < 0.005) in the Danshen 
treated group than that in the control group throughout the time courses. The 
pharmacokinetic parameters of ；S-warfarin in the control group and the Danshen 
treated group were summarized in Table 3.4. Also similar to R-warfarin, both 
groups have the same Tmax (control: 4.0±0.0 hr; Danshen treated: 4.0土0.0 hr). 
The total AUC (control: 115.2士24.5 ftg.hr/ml; Danshen treated: 236.4士63.5 
^g-hr/ml), Cmax (control: 3.4土0.3 jug/ml; Danshen treated: 5.5土0.9>tg/ml)，TVi 
(control: 23.6±4.6 hr; Danshen treated: 30.6±3.7 hr) and Ka (control: 
2.06土0.02; Danshen treated: 2.18土0.04) were significantly higher (P < 0.005) 
in the Danshen treated group than those in the control group. Besides, The Vd 
(199.5土44.3 ml) and CL (4.5土 1.2 ml/hr) in the Danshen treated group were 
significantly lower (P < 0.005) than those in the control group (Vd: 301.9+23.7 
ml; CL: 9.1 土2.4 ml/hr). 
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3.3,2 The Effects of Danshen extract on the Steady State Study 
Figure 3.8 shows the time course for mean prothrombin times in rats after 
daily administration of warfarin in steady state study before and after taken the 
Danshen extract. It was observed that the prothrombin times were significantly 
increased (P < 0.005) from Day 6 to Day 8 (Day 5 (control): 12.9土 1.2 seconds; 
Day 6: 17.5士2.6 seconds; Day 7: 20.8± 2.9 seconds; Day 8: 23.9土3.4) after the 
Danshen treatment. 
The time course of mean plasma R-warfarin concentrations versus time in 
steady state study before and after the Danshen extract treatment were displayed 
in Figure 3.9. Steady state of warfarin was achieved in Day 5 (0.97+0.08 ^tg/ml). 
Significant increases (P < 0.005) in the mean plasma R-warfarin concentrations 
from Day 6 to Day 8 (Day 6: U 4 ± G � 2 _ _ ! Day 7: 1.30土0.21 pg/ml; Day 
8: 1.43土0.20 ptg/ml) were found after the Danshen treatment. 
Figure 3.10 shows the time course of mean plasma S-warfarin 
concentrations versus time in steady state study before and after the Danshen 
treatment. Similar to R-warfarin, there were significant increases (P < 0.005) in 
mean plasma S-warfarin concentrations after treated with Danshen extract from 
Day 6 to Day 8 (Day 5 (control): 1.00土0.07 ^g/ml; Day 6: 1.14土0.09 pg/ml; 
Day 7: 1.25土0.09 pg/ml; Day 8: 1.39±0.15/xg/ml). 
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Figure 3.11 displays the time courses of mean plasma R- and S-warfarin 
concentrations versus time in steady state study before and after treatment with 
Danshen extract for three days. There were no significant difference in mean R-
and S-warfarin concentrations during the whole time courses, no matter before or 
after the Danshen treatment. 
3.4 Discussion 
In the single dose pharmacokinetic study, pharmacokinetic interaction 
between warfarin and Danshen extract was found. The similar rate of absorption 
(Ka) of R- and S-warfarin in the control group indicated that there was no evidence 
of stereoselective property found in the absorption process (Table 3.1). Similar 
Cmax and Tmax suggested that R- and S-warfarin have similar initial bioavailability 
after oral administration of racemic warfarin. Significant (P < 0.005) longer 
elimination half-life (TV2) in S-warfariri was observed compared with that of R-
warfarin, thus, R-warfarin was eliminated faster than S-warfarin. Since both 
enantiomers had no significant difference in the apparent volume distribution (Vd). 
The longer TV2 of S-warfarin was due to the significantly lower clearance (CL) of 
S-warfarin, and a greater total AUC of S-warfarin compared with that of R-
warfarin. This greater AUC of S-warfarin reflects a higher bioavailability of S_ 
warfarin than that of R-warfarin after racemic administration. Previous studies 
observed that S-warfarin has a longer half-life (38.5士4.3) and is a more effective 
anticoagulant than R-warfarin (24.5士2.9 hr) (Baars et al, 1990). In man, 



























































































































































































































































anticoagulant than the R-warfarin (20 - 60 hr) (Breckenridge & Orme, 1972; 
Breckenridge et al” 1973; Hignite 权 c/., 1980; Pratt et al, 1989). 
After three days of Danshen treatment, the mean plasma concentrations 
(Figure 3.5) and pharmacokinetic parameters of R- and S-warfarin were similar 
except the TVi (Table 3.2). The TlA of S-warfarin was significantly longer than 
that of R-warfarin. It was observed that the pharmacokinetic properties of R-
warfarin and S-warfarin became similar after the Danshen treatment. Since both 
enantiomers had similar Vd and CL, the reason of significant longer TVi in S-
warfarin was unknown. 
In Figure 3.6 and Figure 3.7, the overall plasma R- and S-warfarin 
concentrations were significant higher in the Danshen treated group than the 
control group. The increase of the R-warfarin and S-warfarin bioavailability after 
the Danshen treatment could also be seen in the significant increase in total AUC 
(Table 3.3 and Table 3.4), Although the Vd of both enantiomers in the Danshen 
treated group were significant decreased, the TV2 was still significantly longer in 
the Danshen treated group than the control group. This may be due to the 
significant decrease in CL which was caused by the increase in total AUC under 
the same dosage. The mechanisms of increasing the bioavailability of warfarin 
cannot be explained now. The previous study showed that aspirin may enhance the 
hypoprothrombinemic action of warfarin (Sandercock and Dunbabin, 1991). Since 
aspirin alters the structure of the plasma protein (Hawkins, 1969). Therefore, 
aspirin may either displace warfarin or prevent it from binding with the plasma 
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protein. However, there was no evidence to show whether Danshen also has the 
property to displace the protein-bounded warfarin. The Ka was significantly 
increased in the Danshen group compared with the control. Present data cannot 
provide the answer for the mechanisms responsible for the increase in absorption 
rate and increase in the Cmax in the Danshen treated group. It is likely the Danshen 
increases blood flow which indirectly potentiates absorption of warfarin. 
In the steady state study, the prothrombin times (PT) were significantly 
increased after the Danshen treatment, suggesting that Danshen extract interacted 
pharmacodynamically with warfarin. Similar pharmacokinetic interactions were 
also observed in the same study as reflected by the increase in plasma 
concentrations of both enantiomers the Danshen treatment (Figures 3.9 & 3.10.) 
However, the difference between the plasma concentrations of R- and S-warfarin 
in the same group of rats was insignificant throughout the Danshen treating period 
(Figure 3.11). It shows that the extent of increase in plasma concentrations of R-
and S-warfarin was similar. The increase in R- and S-warfarin concentrations 
compliments the significant increase in the prothrombin times. 
In conclusion, the present study provides some evidence of pharmacokinetic 
and pharmacodynamic interactions between Danshen extract and warfarin. 
However, the mechanisms involved in these interactions could not be identified. 
Many drug interactions of warfarin have been reported (Banfield ^ al” 1983; 
Koch-Weser and Seller, 1971; Scott and Orme, 1983). For example, aspirin is an 
antiplatelet drug (Ke, 1982). Aspirin inhibits platelet aggregation by interfering 
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with the release of adenosine diphosphate (ADP) from platelets (Ke, 1982; 
Sandercock and Dunbabin, 1991)., resulting an increase in the bleeding time. 
Although Danshen is also an antiplatelet drug (Chang and But, 1986), there was 
no evidence to show whether the interactions between Danshen and warfarin are 
similar to the interactions between aspirin and warfarin. R- and S-warfarin are 
metabolised by different metabolic pathways (Lewis et al” 1974; Hewick and 
Moreland, 1975; Banfield et al” 1983). R-warfarin is predominantly reduced by 
soluble enzymes to warfarin (R&S) alcohols while S-warfarin is mainly 
metabolized by a cytochrome P-450-dependent, mixed function oxidase (Lewis et 
al” 1974; Banfield et al, 1983). Further investigation are needed to explore the 
mechanisms of the interactions by concentrating on the different metabolic 
pathways of the two stereoisomers, 
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CHAPTER 4 
The Effects of Danggui (Angelica sinensis) on Pharmacokinetics and 
Pharmacodynamics of Warfariii 
4.1 Introduction 
4.1.1 Danggui 
Danggui is the root of Angelica sinensis (Oliv.) Diels (Umbelliferae). It is 
also known as Qingui or Yungui. This herb tastes sweetish and acrid, and has a 
"warm" (yang) property (Chou et al” 1979). It is cultivated chiefly in Minxian 
Country, Gansu Province as well as in the Sichuan, Yunnan, Shanxi, and Hubei 
Provinces (Hsu et al,t 1986). Other herbs of the same family, such as Angelica 
acutiloba (Sieb. et Zucc.) Kita., Angelica gigas Nakai and Levisticum officinale 
Koch, have also been used in medicine, but Angelica sinensis Diels is the most 
widely used and the best known among them (Tang and Eisenbrand, 1992). 
Chinese people began to use Danggui as a remedy for certain diseases over 2000 
years ago and the drug is now still clinically widely used for many diseases. 
At the beginning of this century scientists began to study the chemical 
constituents and the pharmacological actions of Angelica sinensis Diels by using 
modern scientific methods. In recent years, great advances have been made in 
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chemical and pharmacological studies of the drug, for examples, actions on smooth 
muscles of the uterus and on cardiovascular system. 
4.1.2 Chemical Composition 
The root of Danggui contains 0.2-0.4% of volatile oil of which 45% is 
ligustilide; n-butylidene phthalide is a component of the volatile oil with a 
characteristic fragrance. The volatile oil also contains n-valerophenone-O-
carboxylic acid, n-dodecanol and "fragrant-lemon lactone". The root also contains 
fixed oil, palmitic acid, /3-sitosterol, /3-sitosteryl palmitate, sucrose 40%, vitamin 
B12 (0.25 - 0.4 fig/100 g)9 nicotinic acid, folic acid, folinic acid, biotin and 
vitamins A and E. Ferulic acid, succinic acid, uracil and adenine were recently 
isolated from the aqueous extract of the root of Danggui (Chang, 1986). The 
chemical structures of ferulic acid and ligustilide are shown in Figure 4.1. 
4.1.3 Pharmacological Actions 
The pharmacological actions of Danggui can be summarized under the 
following heading: 
(1) Actions on Cardiovascular System 
Cardiac haemodynamic studies showed that the coronary blood flow 
increased after intravenous injection of aqueous extracts of Danggui in 
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Figure 4.1 Chemical structures of ferulic acid and ligustilide 
. » 
. • . • * 
- . . *• % . . . • 
. • o 
106 
. , . . . . 一 - ‘ ' . . . . , , . . . . / ‘ ‘ * • 
. . . . ‘ ,.. • ‘ ‘ ''' . • . ； ‘ ; . . . ’， . ， 
. . . , , ‘ • ： ：、:. . . •'.:. - ..., • r.... . . ‘ • . . . . . . . . . . . ’ • 
anaesthetized dogs and that the coronary vascular resistance decreased. The 
myocardial oxygen consumption also decreased. The heart rate slowed down or 
remained unchanged, while the arterial blood pressure and total peripheral 
resistance were significantly reduced (Chou, 1979). Danggui also increased the 
coronary blood flow of isolated heart in guinea pigs (Pen, 1981). Experimental 
myocardial ischemia in anaesthetized animals and damage to cultured myocardial 
cell due to sugar deficiency and hypoxia were partly relieved by Danggui (Pen, 
1981; Chen, 1990). 
The alcoholic or aqueous extracts of Danggui have been shown to be 
strikingly antagonistic against arrhythmias produced by adrenaline, barium chloride 
(BaCy or digitalis in animals (Pen, 1981; Cha, 1981). Danggui and its 
constituent, ferulic acid, was capable of restoring normal rhythm in ventricular 
muscle after arrhythmia was induced by ouabain. Aconitine-induced arrhythmias 
in anaesthetized rats were effectively prevented when the alcoholic extract of 
Danggui was injected intravenously. It was reported that the ether extracts of 
Danggui had quinidine-like effect and could prolong the atrial refractory period in 
rabbit and abolish atrial fibrillation induced by electricity or acetylcholine in 
anaesthetized dogs. Recent studies showed that Danggui might reduce the action 
potential amplitude (APA) and maximal upstroke velocity of 0 phase (Vmax) and 
prolong the effective refractory period (ERP) and action potential duration (APD) 
of the myocardium in guinea pigs (Wei, 1985). Though Danggui has been used 
clinically for certain arrhythmias, the antiarrhythmic constituents of the drug are 
not known. 
. 1 0 7 . . . 
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It was demonstrated that most preparations of Danggui could induce a 
marked fall in animals' blood pressure (Chou, 1979; Xu, 1980). Danggui had a 
rapid, but a relatively short action. Early reports attributed the fall in blood 
pressure to direct depression of the heart as it was once held that the extract 
contained a substance which was a powerful stimulant to smooth muscles of the 
arteries and might cause constriction of the peripheral vessels. However, recent 
studies have revealed that the cardiac output was not decreased by Danggui. The 
aqueous extracts of the drug have been shown to alleviate smooth muscle spasm 
in the arteries, decreasing vascular resistance and increasing blood flow (Chou, 
1979; Pen, 1981; Xu, 1980). The mechanism of action was considered to be 
associated with the excitation of the acetylcholine, histamine and "-adrenergic 
receptors, respectively (Xu, 1980; Sun, 1988). The drug did not raise the outflow 
from the rabbit ear preparation nor relieve the constriction caused by potassium 
chloride (KC1) in isolated vascular smooth muscles (Pen, 1981). As to the 
constituents affecting blood pressure, it was assumed that the non-volatile 
ingredients of the drug caused a fall In blood pressure and the volatile oils had a 
stimulant action. However, further studies demonstrated that the volatile oil of 
‘ Danggui, when administered intravenously in conscious hypertensive dogs, caused 
a marked fall in blood pressure (Chou, 1979). 
(2) Actions on the Blood System 
According to one of the ancient Chinese pharmacopoeia, Compendium of 
Materia Medica, Danggui plays an important role in regulating and enriching 
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blood. It was reported that Danggui might promote the speed of replenishment of 
erythrocyte and haemoglobin (Hb) from posthaemorrhagic anaemia in rats (Zhou, 
1985). It was considered that the haematopoietic action of the drug was related to 
its constituents, vitamin B12 and polysaccharides (Ma, 1988). 
In 1976, the Institute of Materia Medica, Chinese Academy of Medical 
Sciences, found that Danggui could decrease adenosine diphosphate(ADP)-induced 
platelet aggregation in viYro. Further work along this line showed that, in rats, 
intravenous injection of the aqueous extracts of the drug or one of its constituents, 
ferulic acid, inhibited platelet aggregation induced by adenosine diphosphate or 
collagen and the release of 5-hydroxytryptamine (5-HT) from labelled platelets 
(Yin, 1980). Studies on the mechanism of anti-platelet action indicated that the 
inhibitory effect of Danggui on platelet aggregation might be due to the inhibition 
of cyclo-oxygenase and thromboxane A2 synthetase in arachidonic acid metabolism 
by its constituent, ferulic acid, and subsequent reduced production of thromboxane 
a 2 (TXAj (XU, 1990; Wang, 1988). Danggui and its constituent, ferulic acid, 
might produce a signific^it antithrombotic effect (Xu, 1990). Treatment with the 
decoction of Danggui in rats lowered platelet aggregation and prolonged the time 
of coagulation in vitro. Further haemorrheological studies showed that, after 
patients with acute ischemic apoplexy were injected with Danggui, blood viscosity 
and plasma fibrinogen level declined, the prothrombin time was significantly 
prolonged and the time for erythrocyte and platelet electrophoresis shortened (Tu, 
198¾. These studies revealed that the antithrombotic effect of Danggui was 
associated not only with its anti-platelet aggregation action, but also related to a 
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decrease in the concentration of plasma fibrinogen and changes in the cellular 
surface charge and in blood viscosity. 
(3) Actions on Pulmonary Function 
Ancient Chinese pharmacologists suggested that Danggui was capable of 
depressing cough and relieving dyspnea (Tang and Eisenbrand, 1992). Satisfactory 
results have been achieved in the treatment of bronchial asthma and chronic 
bronchitis with Danggui, and one of its constituents, ligustilide. When an extract 
of the drug was given orally to patients with chronic obstructive pulmonary 
diseases for 50 to 60 days, the forced expiratory volume in the first second 
increased (Public Health bureau of Fanxian Country, 1978). The drug was used 
in the treatment of severe pulmonary diseases with the result of lowering the 
mortality rate, increasing partial pressure of oxygen (P02), decreasing partial 
pressure of carbon dioxide (PCO^ and improving electrocardiogram (ECG). It has 
been demonstrated that the constituents of Danggui, n-butylidene phathalide and 
ligustilide, might relax bronchial smooth muscles and thus protect guinea pigs from 
experimental bronchial asthma (Cui, 1982; Tao, 1984). Besides, Danggui could 
reduce hypoxemic pulmonary hypertension and improve pulmonary circulation. 
(4) Actions on Immunological Function 
In 1974，it was found that Danggui could boost the clearance function of 
mononuclear phagocyte system in mice using13 ^ -labelled plasma protein clearance 
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test. Recent studies showed that the clearance rate of Congo red in mice was 
significantly increased after administration of aqueous extracts of Danggui and its 
constituents, ferulic acid and polysaccharide (Xu, 1981). The phagocytosis 
percentage and phagocytosis index of peritoneal macrophage in mice were also 
increased when sodium ferulate was given either subcutaneously or orally for 4 
days. It was observed that, after the administration of aqueous Danggui extract, 
the titre of serum antibody elevated and the proliferation of lymphocytes 
accelerated. Danggui extract and its constituent, ferulic acid, could dramatically 
increase the synthesis of DNA and protein in lymphocyte by Concanavalin A (Con 
A) stimulation and the production of interleukin-2 (Wu, 1989). The results indicate 
that Danggui has an immunomodulating action. 
(5) Actions on Smooth Muscles of the Uterus 
Since ancient times, Danggui has been highly valued as an important 
remedy for gynaecologic disorders. Scientists have found that Danggui has certain 
effects on the uteri of both animals and humans. Experimental studies have shown 
that the drug contains two components: one component inhibits while the other 
stimulates the uterus. The inhibitory component consists chiefly of essential oils 
which inhibit the contraction of isolated uteri in animals, but less markedly after 
intravenous administration (Pi, 1955; Lu, 1954). Ligustilide is probably the active 
ingredient in the essential oils of Danggui which is capable of inhibiting smooth 
muscles of the uterus. The excitatory component, which is soluble in water, 
alcohol and some other organic solvents, can strengthen the contractions and 
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increases the tone or rhythm of uterine smooth muscles (Pi, 1955; Lu, 1954). 
(6) Analgesic and Anti-nociceptive Actions 
Tanaka investigated the anti-nociceptive activities of aqueous extracts of 
different varieties of Danggui prepared by chemical fractionation and bioassay in 
1977. The results showed the Angelica sinensis Diels and Angelica acutiloba var. 
acutiloba Kitagawa had anti-nociceptive activity which suggested the presence of 
analgesic effects. Seven active compounds which could inhibit acetic acid-induced 
writhing in mice were isolated from Angelica acutiloba var. acutiloba Kitagawa 
and identified as falcarinolone, falcarindiol, facarinol, choline, scopoletin, 
nubelliferone and vanillic acid. Among them, choline, scopoletin, nubelliferone 
and vanillic acid are also present in Angelica sinensis Diels. The latter was 
administered intercostally to 105 patients who had received surgical operation on 
the chest. The postoperative pain was significantly relieved. The drug might also 
be used for the treatment of headache. 
It was reported that Danggui might alleviate heart, liver and kidney damage 
induced by sugar-deficiency and hypoxia, D-galactosamine, and aminonucleoside 
respectively, and immune depression by glucocorticoid (Chen, 1990; Xiong, 1982; 
Zhang, 1986; Luo, 1987). The drug might also partly inhibit Aflatoxin Bx 
(AFB^-induced hepatocarcinogenesis (Yan, 1986). The drug might alleviate liver 
damage induced by D-galactosamine, protect glycogen in the liver from depletion 
and increase the activity of ATPase. In clinical trials, the drug was used for 
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chronic hepatitis and cirrhosis of the liver with therapeutic effects (Tang and 
Eisenbrand, 1992). 
4.1.4 Aims 
Based on the above-mentioned pharmacological actions, it is recognized that 
Danggui is widely used clinically in the treatment of many diseases. Danshen is 
a common herbal medicine and is freely available as proprietary TCM preparations 
in Hong Kong and in China. Moreover, many women take Danggui soup as an 
medical care treatment before and after labour when they are co-administering 
western drugs (WPCMIR, 1991). Hence, the risk of drug interactions between 
Danggui and warfarin may occur. Besides, It has been observed that patients who 
were on routine warfarin therapy suffered adverse side effects when they self-
medicated with the TCM, 
In this chapter, Danggui was used as a model TCM administered orally 
into the rabbits for investigating the interactions between Danggui and warfarin. 
The effects of Danggui on pharmacokinetics and pharmacodynamics of warfarin 
in the rabbits were investigated. 
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4.2 Materials and Methods 
4.2.1 Chemicals and reagents 
The reagents were the same as those used in Chapter 2. Warfarin was 
purchased from Sigma Chemical Co. (St Louis, MO, U.S.A.). Acenocoumarol 
was supplied as gift (Ciba-Geigy, Basle, Switzerland). Methanol (HPLC grade) 
was purchased from Mallinckrodt Speciality Chemical Co (Paris, KY, U.S.A.). 
Diethyl ether was obtained from E. Merck (Darmstadt, Germany). Hydrochloric 
acid (2M) was washed with diethyl ether, and water was double-distilled before 
use. The thromboplastin reagent, Simplastin, was supplied from Organon Teknika 
Corporation. (Durham, NC, U.S.A.). The Danggui roots were purchased from Hip 
Hing Lung Chinese Medicine Store (Hong Kong). 
4.2.2 Preparation of Danggui aqueous extract 
Danggui was authenticated pharmacognostically by the Chinese Medicinal 
Material Research Centre (CMMRC) of the Chinese University of Hong Kong. 
The preparation of Danggui extract was similar to that for Danshen aqueous 
extract which was described in Chapter 2. The Danggui root (1 kg) was firstly cut 
into small pieces (Picture 3.1), and soaked in double-distilled water (3 L) 
overnight at room temperature. On the next day, a further 500 ml double-distilled 
water was added and boiled for 3 hours. The mixture was filtered by a double-
layer bandage. The filtrate was collected and left overnight at room temperature. 
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Picture 4.1 Danggui (Angelica sinensis) Roots 
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The supernatant was then pipetted out and the precipitate was filtered once again 
through filter paper (15 cm, Qualitative Grade 1, Whatman, France). The filtrate 
was added into the supernatant solution. The whole solution was dispensed into 
smaller containers (10 ml) and then concentrated to dryness by a freeze-dryer 
under reduced pressure. The residue was dissolved to make up to approximately 
2 g dried weight of Danggui root per ml (500 ml). The Danggui extraction solution 
was stored at -4°C before use and then thawed before use. 
4.2.3 Treatments 
4.2.3.1 Animals and Sampling Method 
Male New Zealand white rabbits weighing from 3.5 to 4 kg were used. 
Animals were allowed free assess to a standard diet and tap water. The animals 
were fasted overnight before oral administration of the drugs and food was 
resumed 4 hours post dose. 
Blood samples (1 ml) were collected from the vein of the ears. Treatment 
of the blood samples were similar, to methods as outlined in Chapter 2. The freshly 
drawn blood was mixed thoroughly with sodium citrate (3.8 %) in a ratio of 9:1 
(100 fil). After centrifugation for 10 min. at 3000xg, the plasma was collected for 
HPLC analysis and PT measurement. 
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Single Dose Study: The rabbits (N=6) were administered a single dose (2 mg/kg, 
dose volume: 1 ml) of warfarin subcutaneously. Blood samples were collected at 
0, 4, 8, 12, 24, 36. 48 and 72 hours post dose. After 4 days, the same group of 
rabbits were treated with a dose of Danggui extract (2 g/kg, dose volume=4 ml) 
orally twice daily for three days. After three days treatment with the Danggui 
extract, warfarin was administered subcutaneously (2 mg/kg, dose volume=l ml). 
Blood samples (1 ml) were collected at same time interval post dose. Plasma was 
separated by centrifugation and used for prothrombin time (PT) measurement and 
stored at -20°C before HPLC analysis. 
Steady State Study : The rabbits (N=6) were administered subcutaneously (0.6 
mg/kg/day, dose volume= 1 ml) warfarin daily to maintain a steady state. After 
four days of warfarin treatment, the steady state was maintained. The rabbits were 
treated with Danggut extract (2 g/kg, dose volume口4 ml) twice daily for three 
days when they were still treated with the same dose of warfarin daily. The blood 
samples (1 ml) were collected daily. The plasma was then centrifugation for PT 
measurement and stored at -20°C before HPLC analysis. 
4.2.4 High Performance Liquid Chromatography 
The apparatus and conditions were the same as outlined in Chapter 2. The 
high performance liquid chromatography system consisted of a Hewlett Packard 
(HP) 1050 series pumping system and multiple wavelength detector (Waldbronn, 
Germany), a Model 7125 syringe loading sample injector with a 200^1 loop 
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(Rheodyne Incorporated, Cotati, CA, U.S.A.) and a Model L6512 chart recorder 
(Linseis, Germany). The eluates were analyzed by passing through a Hiber pre-
column (50 mm x 4.6 mm I.D. packed with Perisorb RP-8 30 >tm C18 reverse 
phase) which were obtained from E. Merck (Darmstadt, Germany), and a Waters 
pBondapak C18 analytical column (8 mm x 10 cm I.D.) which was purchased from 
Waters (Milford, MS, U.S.A.). 
The operation conditions for the HPLC system were: mobile phase, 
consisting of 65% methanol with 10 mM phosphate buffer at pH 5.7 which was 
filtered through a 0.22 fim filter and simultaneously degassed under vacuum; flow 
rate, 1.5 ml/min; temperature, ambient (25 土 1�C); multiple wavelength detector, 
X=215 nm. During the assay, the mobile phase was recycled. 
4.2.4.1 Standard Solutions 
Stock solution of warfarin and acenocoumarol (100 /xg/ml) in methanol 
were prepared and stored frozen as aliquots (1 ml) at -20°C. Standard solutions 
of 10 jLtg/ml warfarin and 12 fig/ml were prepared and kept at 4°C. Standard 
solutions were prepared freshly every two weeks. 
4.2.4.2 General assay procedures 
The plasma warfarin concentration was determined by a modification of a 




4.2.5 Prothrombin time measurement 
The apparatus used in prothrombin time (PT) test include a Coagulometer 
KC 4A with CR-A computer, and stainless steel balls (no. Z03200), plastic tubes 
(no. 834011) and glass tubes (15 mm I.D.) as accessories (Heinrich Amelung 
GmbH, Lehbrinksweg, Lemgo-l-Lieme, Germany). Other apparatus used included: 
10 ml capacity centrifuge tubes with well fitted, telfon-lined screw caps (Sovirel, 
Levallois-Perret, France), 15 ml capacity evaporation tubes with finely tapered 
bases. 
4.2.5.1 Prothrombin Time (PT) Test 
The one-stage prothrombin time test was performed (Sawyer and Raasch, 
1984). The procedure is same as described in Chapter 2. 
4.2.6 Data Analysis 
•, , / ‘ ：. 
The plasma concentration data were analyzed by a non-compartmental 
method (Chapter 1). The data was analyzed by a BASIC computer program, 
PKCALC (Shumaker, 1986), which performs standard statistical and 
pharmacokinetic analysis of multisubject data sets (see Chapter 1). The plasma 
warfarin concentration-time data associated with the terminal phase were evaluated 
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by the program for calculating the regression line using standard least squares 
linear regression techniques. 
4.2.7 Statistical analysis 
The data were analyzed by the paired Students' t-test in both the single dose 
study and in the steady state study. A value was considered significantly different 
from the control value if it fell outside the 95% confidence limits (P<0.05). 
4.3 Results 
4.3.1 Effects of Danggui in Single Dose Study of Warfarin 
The mean prothrombin times (PT) during three days Danggui treatment 
period are shown in Figure 4.2. It was observed that there was no significant 
change in PT (Day 0 (control): 6.6土0.1 seconds; Day 1: 6.0土0.4 seconds; Day 
2: 6.0土0.4 seconds; Day 3: 6.0+0.3 seconds). This suggested that the Danggui 
extract itself did not affect blood coagulation. 
Figure 4.3 displays the profiles of mean prothrombin times versus time 
after subcutaneous administration of warfarin alone and three days oral treatment 
with Danggui extract. The longer PTs were reached at 36 hours post dose in both 
treatments (control: 11.0土0.4 seconds; Danggui treated: 9.8土0.6 seconds). And 
the mean PTs were significantly lower after the Danggui treatment at 24 hours 
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(control: 8.8土0.5 seconds; Danggui treated: 7.9土0.7 seconds; P < 0.05), 36 
hours (control: 11.0土0.4 seconds; Danggui treated: 9.8土0.6 seconds; P < 0.01) 
and 48 hours (control: 9.0+0.5 seconds; Danggui treated: 7.9+0.6 seconds; P < 
0.01) post dose compared with the mean PTs without the Danggui treatment. 
The profiles of mean plasma warfarin concentrations versus time after 
subcutaneous administration of warfarin alone and three days treatment with 
Danggui extract was shown in Figure 4.4. It was observed that there was no 
significant difference in plasma warfarin concentrations after both treatments. The 
pharmacokinetic parameters of warfarin in rabbits after single dose of warfarin 
alone and after Danggui extract treatment are summarized in Table 4.1. There 
was no significant difference in the pharmacokinetic parameters of warfarin in 
between treatments including in total AUC (control: 82.4 士 12.9 /ig-hr/ml; Danggui 
treated: 75.7土9.6 /ig-hr/ml), Cmax (control: 7.0土 1.6 終g/ml; Danggui treated: 
7.5土0.5 /xg/ml), Tmax (control: 2.0土0.0 hr; Danggui treated: 2.0土0.0 hr), TVi 
(control: 13.0土 1.4 hr; Danggui treated: 12.0土 1.2), Vd (control: 465.5士83.9 ml; 
Danggui treated: 468.8土96.3 ml) and CL (control: 24.8土4.0 ml/hr; Dmiggui 
treated: 26.8土3.2 ml/hr). It suggested that Danggui extract did not alter the 
i 
pharmacokinetic properties of warfarin in rabbits. 
4.3.2 Effects of Danggui In Steady State Study of Warfarin 
Figure 4.5 shows the graph of the mean prothrombin times versus time in 
the steady state study. After 4 days of warfarin treatment, The steady state was 
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reached and maintained because the PT became steady (13.0土2.9 seconds) and it 
acted as a control to compare the PTs thereafter. The PTs were significantly 
increased (P < 0.01) after treatment of Danggui extract to rabbits for two and 
three days (Day.6: 23.2士7.1 seconds; Day 7: 27.0土8.4 seconds). However, 
16.7% of rabbits died in Day 6 and Day 7 respectively as they were treated with 
Danggui extract for two and three days. Since 16.7% of rabbits died in Day 6 and 
Day 7 respectively, the percentage of rabbits which were included into account of 
statistical analysis were 83.3% in Day 6 and 66.7% in Day 7. 
Figure 4.6 displays the graph of mean plasma warfarin concentrations 
versus time in the steady study. It is observed that the steady state was reached in 
Day 4 (0.24 ±0.08 /ig/ml): There were no significant difference in mean plasma 
warfarin concentration after the Danggui treatment (Day 5:0.26土0.09 fig/ml; Day 
6: 0.31±0.09 饨 / m l ; Day 7: 0.28±0.09 飓 / m l ) . 
4.4 Discussion 
This present study in the rabbits showed some evidence in 
pharmacodynamic interaction, but not in pharmacokinetic interaction, between 
warfarin and Danggui extract. In the single dose study, no significant change in 
the mean plasma warfarin concentrations was observed after the Danggui treatment 
(Figure 4.4). Besides, the pharmacokinetic parameters of warfarin were not altered 
significantly (Table 4.1). These results suggested that Danggui extract did not 
interfere the pharmacokinetic properties of warfarin. The inhibitory activities of 
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warfarin in the vitamin K-dependent carboxylation of coagulation factors (II, VI， 
IX and X) was not altered. The mean prothrombin times (PT) were decreased 
significantly from 24 hours to 48 hours post dose after the Danggui treatment 
(Pigure 4.3). The pharmacokinetic data of warfarin did not correlate with the 
decrease in PT. Furthermore, no significant difference in PT was observed when 
Danggui extract was administered alone (Figure 4.2). The decrease in PT was 
therefore not due to Danggui extract itself. The pharmacodynamic interaction 
• between warfarin and Danggui is still unknown. 
, In the steady state study, some pharmacodynamic interaction between 
warfarin and Danggui extract were observed. The significant increase PTs on Day 
6 and Day 7 showed some evidence of the pharmacodynamic interactions between 
warfarin and Danggui extract (Figure 4.5). The mean plasma warfarin 
concentrations in Day 6 and Day 7 were not increased significantly. Hence, the 
increase in PTs was not due to the iteration of mean plasma warfarin 
concentrations (Figure 4.6). Similar to the single dose study, only 
pharmacodynamic interaction was observed. Moreover, 16.7% of rabbits died after 
treatment with Danggui on Day 6 and Day 7 respectively. Hence, there was some 
务 toxic effects causing death of the rabbits after treatment with Danggui extract. The 
toxic effect was not due to Danggui extract itself because in the single dose study 
no death of rabbits was observed when Danggui was administered alone. 
Interactions between various western drugs and warfarin have been 
attributed to differential effects on the hepatic metabolism of warfarin (Toon et al., 
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1986 Hewick and McEwan, 1973; Choonara et al, 1986) A significant alteration 
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in the metabolic disposition of warfarin would be expected to lead to observable 
changes in prothrombin times Warfarin is highly bound to plasma proteins. 
Displacement by drugs such as clofibrate leads to increased free fraction, 
unchanged free concentration, and an increase in the clearance of total warfarin 
and in its volume of distribution (Bjornsson et al” 1979). Thus, since the 
pharmacokinetics of total warfarin was unchanged during Danggui treatment, the 
results of this study suggested that Danggui alters neither the protein binding nor 
the metabolism of warfarin. 
In conclusion, the pharmacodynamic interaction between warfarin and 
Danggui was difficult to explain. Further investigations are required to explore the 
possible mechanisms. As death of rabbits was observed in the steady study, caution 
is necessary for advising patients who self-medicate with Danggui during warfarin 
treatment. 
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CHAPTER 5 
General Conclusion 
Danshen and Danggui are popular herbal medicines freely available as 
proprietary TCM preparations in Hong Kong and in China. Danshen has been a 
drug of choice for treating cardiovascular diseases such as angina pectoris (Leu, 
1983) and myocardial infarction (Wang ^ al” 1980). Danggui has been used as 
a remedy for certain diseases such as gynaecologic disorders (Pi, 1955) and 
arrhythmias (Wei, 1985). Many people in this region often add these TCM as 
ingredients in their cooking, as alternative medical treatment or even to supplement 
western medical treatment (WPCMIR, 1991). Therefore, the risk of drug 
interactions may occur: In this project, the effects of Danshen and Danggui on the 
pharmacokinetics and pharmacodynamics of warfarin were studied. 
The single dose study after Danshen treatment showed some evidence of 
pharmacokinetic and pharmacodynamic interactions between warfarin and Danshen 
extract. After three days of treatment with Danshen extract, significant alterations 
were observed in the plasma concentration-time profile of warfarin (Figure 2.4) 
and in the prolongation of prothrombin time (PT) (Figure 2.5). The significant 
alteration in PT was due to the possible inhibition of the vitamin K-dependent 
carboxylation of coagulation factors II, VII，IX and X (Park, 1988). The Danshen 
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extract also affected the warfarin bioavailability because the plasma warfarin 
concentrations in the Danshen treated group were significantly higher than that of 
the control group over the 24 hours post dose period (Figure 2.4). In particular, 
the significantly higher AUC4容 of warfarin indicated that Danshen extract would 
increase the initial bioavailability of warfarin (Table 2.1). There was no significant 
difference between the control and test groups in the total AUC芯 of warfarin. The 
Cmax for warfarin was increased in the Danshen treated group. There was no 
significant change in PT during the Danshen treatment period between the Danshen 
treated group and the control group (Figure 2.5). The result showed that Danshen 
extract itself did not have any anticoagulating effect. Significant increases in PTs 
were observed after a single dose of warfarin administration in the Danshen treated 
group in 2 days post dose. Since there was no significant change in the clearance 
(CL), the shortening of elimination half-life (TV2) in the Danshen treated group 
was due to possibly a fall in volume of distribution (Vd) (Table 2.1). The fall in 
Vd cannot be explained at present, one possibility is that Danshen might inhibit 
warfarin uptake into liver. Warfarin hepatic uptake and hepatic metabolism have 
been shown to be governed by distinct processes such as metabolized by 
cytochrome P-450 system and extracted warfarin from hepatic portal vein into the 
liver cells in the rat (Govell, 1983). It means that the rate of warfarin uptake in the 
liver is different from the rate of metabolism of warfarin in liver. 
In the single dose pharmacokinetic study of R- and S_ warfarin after the 
Danshen treatment, both plasma R- and S-warfarin concentrations were 
significantly increased (Figure 3.6 and Figure 3.7). There were increases in total 
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AUC of both R- and S-warfarin after the Danshen treatment (Table 3.3 and Table 
3.4). Although the volume of distribution (Vd) of the Danshen treated group was 
decreased, the elimination half life (7¼) was still significantly longer in the 
Danshen treated group than the control group. Longer TV2 may be due to the 
decrease in clearance (CL) which was caused by the increase in total AUC under 
the same dosage. The similar rate of absorption (Ka) of both enantiomers in the 
control group indicated that there was no evidence of stereoselective property 
found in the absorption process (Table 3.1). Besides, similar Cmax and Tmax 
suggested that R- and S-warfarin have similar initial bioavailability after orai 
administration of racemic warfarin (Table 3.1). It was observed that S-warfarin 
had longer TV2 compared with that of R-warfarin indicating that R-warfarin was 
eliminated faster than S-warfarin. The greater AUC of S-warfarin showed that the 
bioavailability of S-warfarin is larger than that of R-warfarin. These results were 
similar to the previous studies that S-warfarin has a longer half-life (38.5士4.3 hr) 
and is a more effective anticoagulant than R-warfarin (24.5 土2.9 hr) (Baars et al” 
1990). In man, S-warfarin is a more potent anticoagulant than the R-warfarin, S-
warfarin has the shorter half-life (18 - 35 hr; R-warfarin: 20 • 60 hr). 
(Breckenridge and Orme, 1972; Hignite et al, 1980; Pratt et al” 1989). 
The mechanisms of the increase in the bioavailability of warfarin cannot be 
explained. Warfarin is one of the probe drugs use for investigating drug 
interactions. A large number of reports of drug interactions with warfarin has been 
published (Koch-Weser and Sellers, 1977; Scott and Orme, 1983). For example, 
cimetidine inhibits warfarin metabolism and potentiates its effect (Bell et al.， 
. . . : : . . . . 1 3 3 
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1981). Cimetidine binds to cytochrome P-450 and it is a potent inhibitor of the 
microsomal mixed-function oxidase system thus inhibiting warfarin metabolism 
(Sedman, 1984). Hepatic microsomal enzyme-inducing drugs increase warfarin 
elimination and reduce the anticoagulant effect. Examples are carbamazepine, 
phenobarbitone and rifampiein (Scott and Orme, 1983). Phenylbutazone is a well-
documented example of a drug which stereoselectively inhibits warfarin 
metabolism (Banfield et al” 1983). Some other non-steroid anti-inflammatory 
drugs such as meclofenamic acid, mefenamic acid, piroxicam and azapropazone 
also potentiate the anticoagulant effect (Sellers and Koch-Weser, 1970). Amongst 
the drug-drug interactions of warfarin published, aspirin was one of the drugs 
which can increase the bioavailability of warfarin by displacing warfarin or 
preventing it from binding with the plasma protein (Hawkins, 1969; Sandercock 
and Dunbabin, 1991). Danshen inhibits platelet aggregation similar to the 
antiplatelet properties of aspirin which may enhance the hypoprothrombinemic 
action of warfarin (Sandercock and Dunbabin, 1991). However, there was no 
evidence to show that the interactions between Danshen and warfarin is similar to 
that between aspirin and warfarin. 
The steady state study after oral administration of Danshen extract showed 
that the plasma warfarin concentrations in the rats after treatment with Danshen 
extract or Commercial Danshen extract were increased (Figure 2.6 and Figure 
2.7). However, pharmacodynamically, both Danshen extracts did not affect the PT 
at warfarin steady state after the treatment (Figure 2.9). The two Danshen extracts 
did not show any significant difference in both pharmacokinetic and 
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pharmacodynamic aspects. As the measured PT reflects a balance between the rate 
of clotting factors synthesis and the rate of clotting factors degradation (Choonara 
et al” 1985), warfarin affects only the rate of clotting factors synthesis which can 
be calculated from a knowledge of the PT and by making an assumption regarding 
the rate of clotting factors degradation (Nagashima et al., 1969; Choonara et al.， 
1985). Thus, although the plasma warfarin concentrations were significantly 
increased, the PTs were not significantly altered which may probably due to the 
decrease in the rate of clotting factors degradation. 
The steady state study of R- and S-warfarin after intraperitoneal Danshen 
treatment showed that both plasma R- an S-warfarin concentrations were 
significantly increased (Figure 3.8, Figure 3.9 and Figure 3.10). The PT increase 
in this study was contradictory to that after the oral Danshen treatment. It showed 
that Danshen would only affect the PT when it was administered intraperitoneally, 
but not orally. The results suggested that some active ingredients in Danshen 
extract, which would increase the PT at warfarin steady state, may not be absorbed 
in gastrointestinal tract after oral administration of Danshen extract. Thus, from 
this observation, Danshen extract intraperitoneal injection treatment is more 
susceptible to pharmacodynamic interaction with warfarin at steady state than the 
/ . • 
oral administration of Danshen. 
Both the single dose and steady state studies after the Danggui treatment 
showed some evidence in pharmacodynamic interaction, but not in pharmacokinetic 
interaction, between warfarin and Danggui. In the single dose study, there was no 
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difference in the mean plasma warfarin concentrations after the Danggui treatment 
(Figure 4.4)‘ Besides, the pharmacokinetic parameters of warfarin were not altered 
(Table 4.1). These results suggested that Danggui did not interfere the 
pharmacokinetic properties of warfarin. The inhibitory activities of warfarin in the 
vitamin K-dependent carboxylation of coagulation factors (II, VII, IX and X) was 
not altered. The mean prothrombin times (PT) were decreased from 24 hours to 
48 hours post dose after the Danggui treatment (Figure 4.3). The pharmacokinetic 
data of warfarin did not correlate with the decrease in PT. Moreover, no 
difference in PT was observed when Danggui extract was administered alone 
(Figure 4.2). The decrease in PT was therefore not due to Danggui extract itself. 
In the steady state study, only pharmacodynamic interactions between 
warfarin and Danggui were observed, but not in pharmacokinetic interaction. The 
significant increase PTs on Day 6 and Day 7 showed some evidence of the 
pharmacodynamic interactions between warfarin and Danggui extract (Figure 4.5). 
The mean plasma warfarin concentrations in Day 6 and Day 7 were not increased 
significantly. Hence, the increase in PTs was not due to the alteration of mean 
plasma warfarin concentrations (Figure 4.6). Moreover, overall 33.4% of rabbits 
died after the Danggui treatment. The result showed that there was some toxic 
.• “ f ^ .  
effect to cause death of rabbits observed after Danggui treatment. The toxic effect 
was not due to Danggui extract itself because in the single dose study no death of 
rabbits was observed when Danggui was administered alone. 
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Interactions between various western drugs and warfarin have been related 
to differential effects on the hepatic metabolism of warfarin (Toon et al” 1986; 
Hewick and McEwan, 1973; Choonara et al.y 1986). An alteration in the 
metabolic disposition of warfarin would be expected to lead to observable changes 
in prothrombin times. Warfarin is highly bound to plasma proteins (Park, 1988). 
Displacement by drugs such as clofibrate leads to increased free fraction, 
unchanged free concentration, and an increase in the clearance of total warfarin 
and in its volume of distribution (Bjornsson et al” 1979). Thus, since the 
pharmacokinetics of total warfarin was unchanged during Danggui treatment, the 
results of this study suggested that Danggui alters neither the binding nor the 
metabolism of warfarin. 
In conclusion, this project provided some evidence of drug interactions 
between warfarin and two commonly used TCM, Danshen and Danggui. It also 
showed the risk of drug interactions that may occur when TCM and western 
medicine are coadministered. Hence, caution is necessary for advising patients who 
self-medicate with Danshen or Danggui during warfarin treatment. Further 
investigations are required to explore the possible mechanisms between Danshen-
warfarin interactions and Danggui-warfarin interactions. 
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